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Abstract
A research report from the Centers for Disease Control and Prevention (CDC) indicated
that more than 50% of people with diabetes mellitus (DM) in the United States (U.S.)
also have arthritis. The diabetes population is disproportionately affected by arthritis, but
there has been limited and inconsistent research to confirm the association between type
2 diabetes mellitus (T2DM) and rheumatoid arthritis (RA). The current study aimed to
identify an association between T2DM and RA for noninstitutionalized U.S. adults
between 1999 and 2012 using a nationally representative sample from the National
Health and Nutrition Examination Survey (NHANES) database (n =31,488 ). A
quantitative, cross-sectional investigation was conducted to determine if patients with
T2DM had an increased prevalence of RA. The current study also sought to identify
characteristics that could affect the association between both groups and the prevalence
of cardiovascular disease (CVD) in this population. Prevalence and adjusted odds ratios
(OR) using logistic regression were calculated. The results show evidence of a strong
association between T2DM and concomitant RA. Prevalence of RA was significantly
higher in participants with T2DM compare to those without T2DM. Important factors in
this association were gender, ethnicity, education, disability, and work functioning. The
prevalence of CVD and adjusted OR of association were doubled in participants with
T2DM and RA when compared to participants who had just one of the conditions; the
OR of association was quadrupled when compared to those without this comorbidity.
This study may provide patients and health care providers with a better understanding of
the need for management of both conditions in a interdisciplinary manner.
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Chapter 1: Introduction to the Study
Background
The prevalence of diabetes has reached epidemic proportions worldwide; more
than 347 million people, corresponding to almost 7% of the world's population, are
estimated to live with diabetes (IDF, 2012; WHO, 2013a). The number is expected to
grow to more than 552 million by 2030, corresponding to approximately 8% of the
world's total population (IDF, 2012). Diabetes caused 4.8 million deaths and cost more
than $471 billion in healthcare expenses in 2012 (IDF, 2012). In the United States,
diabetes affects 25.8 million people of all ages, or approximately 8.3% of the U.S.
population (CDC, 2011a). Several comorbidities have been related to diabetes, and some
of them are considered complications of the same condition (ADA, 2013a). As part of the
public health strategy, it is important to consider everything affecting health issues. For
example, in case of diabetes, it is essential to work in a interdisciplinary manner to (a)
identify emerging issues and opportunities, and (b) develop ways in which different
components can work together to build upon each other’s areas of expertise. This
approach stimulates collaborations and helps ensure that health efforts are coordinated,
not duplicated.
Arthritis is not widely recognized as comorbid with diabetes and is notconsidered
as part of the potential difficulties that patients and care providers may encounter when
managing diabetes (ADA, 2013a). Data from the CDC indicated that more than half of
people with diabetes also suffer from arthritis; however, no clear evidence is available
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that indicates an association between type 2 diabetes mellitus (T2DM) and rheumatoid
arthritis (RA), one of the most common types of arthritis (CDC, 2008; CDC, 2010b).
The incidence and prevalence of RA are difficult to define, and changes in trends
are difficult to predict. The prevalence of RA varies between 0.3% and 1% globally; it is
more common in women and in developed countries. The World Health Organization
(WHO) indicated that within 10 years of onset , at least 50% of patients in developed
countries are unable to hold down a full-time job (Woolf & Pfleger, 2003; WHO, 2013b).
An estimated 1.5 million people in the United States were affected by RA in 2007 (CDC,
2013a; Myasoedova et al., 2010).
Arthritis and other rheumatic conditions are the most common cause of disability
among U.S. adults and have been for the past 15 years. Forty-two percent of adults with
doctor-diagnosed arthritis report activity limitations due to arthritis (CDC, 2010b).
Considering diabetes and the effect on disability, the National Health Interview Survey
(NHIS) has found that disability affects an estimated 20–50% of patients with diabetes. In
general, patients with diabetes report rates of disability that are substantially higher than
those reported by the general U.S. population (CDC, 2011a). The consequences of
disability are extensive, including increased absenteeism, lack of employment, lower
income levels, limited access to health care services, decreased health status, and lower
quality of life. Evidence also has indicated that DM and RA are equally associated with
increased risk of cardiovascular disease (CVD; Kitas & Erb, 2003; Karanasos et al.,
2012; Lindhardsen et al., 2010; Peters et al., 2009; Peters et al., 2010; Van Halm et al.,
2009), which is identified as the major cause of death in the United States (CDC, 2011b).
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However, no data are available that reflect how the prevalence of CVD is affected by the
comorbidity of T2DM and RA.
Researchers have reported data that indicate a potential association between
T2DM and RA; however finding an association between these two important conditions
was not the main purpose for most of these investigations. Only a few studies have been
conducted to evaluate the potential association between T2DM and RA, and results are
not consistent. Simard and Mittleman concluded that there was no association between
RA and DM; however, this study was limited because it included only people aged 60
years old and over and did not include the general population and it evaluated data only
from 1988 to 1994 (Simard & Mittleman, 2007). Tentolouris et al. (2008) evaluated the
presence of concomitant RA in patients with DM and followed studythem for at least 10
years, but was not able to reach any conclusions due to the relatively small cohort.
Solomon et al. (2010a) examined the risk of DM in patients with RA : RA appeared to be
associated with an increased risk of DM. However, this increased risk decreased with
age. According to the authors, , this study needs replication. Dubreuil et al. (2012)
evaluated the risk of incident DM in RA and found that the risk was significantly
elevated only with increased body mass index (BMI) and smoking.
Data from other studies have demonstrated different results when an association
between DM and RA is evaluated as an exploratory objective. Based on these studies, it
is not clear how these important conditions are related, which is an important gap to
assess in order to be able to manage this comorbidity adequately.
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Since the literature has shown mixed results with small direct and indirect studies,
the next logical step is to conduct a larger and more direct investigation to evaluate the
association between T2DM and RA and potentially relevant characteristics. The current
study included a cross-sectional evaluation with a bigger sample, considering all adult
age ranges (over 20 years old) and using more recent data (19992012) from NHANES.
This study has implications for social change. This resulting data may give care
providers and patients a better understanding of how to manage both conditions using an
interdisciplinary approach. Results may also support the creation of adequate public
health interventions for preventing arthritis in patients with diabetes and for managing
modifiable lifestyle characteristics for both conditions.
This chapter covers the following topics: the problem and the research questions
to be addressed in this investigation,. the theoretical foundation and a brief summary of
the literature , the nature of the research, and the study’s assumptions, limitations, scope,
and significance.
Statement of the Problem
CDC data from 2008 has indicated that more than half of people with diabetes
also suffer from arthritis in general; however, no association between T2DM and RA, a
common type of arthritis, has been demonstrated (CDC, 2008). There are several reasons]
why association could exist between these two conditions: (a) both conditions are linked
to CVD (Stamatelopoulus et al., 2009b; Van Halm et al., 2009; Lindhardsen et al., 2010;
Peters et al., 2009; Stamatelopoulos et al., 2009a); (b) systemic inflammation is one of
the characteristics of RA (CDC, 2012a); at the same time it has been demonstrated that
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these characteristics of inflammation predispose the development of insulin resistance
and T2DM (Sattar et al., 2003); (c) markers of inflammation like C-reactive protein
(CRP) and interleukin 6 predict T2DM (MacLennan, 2007); and (d) medications
commonly used in RA, like glucocorticoids, are expected to contribute to insulin
resistance, which increases the risk of developing T2DM (Wasko et al., 2011; Antohe et
al., 2010; Antohe et al., 2012; Bili et al., 2011; Solomon et al., 2010b; Solomon et al.,
2011; Sasaki et al., 2010; Yokota & Igaki, 2012).
Diabetes is a broadly recognized public health issue and, as part of a public health
strategy to improve health, it is important to consider all related health issues and to
investigate them in a interdisciplinary manner (ADA, 2013a; ADA, 2013b; ADA, 2014).
RA is not widely recognized as a comorbidity of diabetes and thus is not managed as
such (CDC, 2012a). The conclusions in the literature about the association between
T2DM and RA are inconsistent (Simard and Mittleman, 2007; Tentolouris et al., 2008;
Solomon et al., 2010a; Dubreuil et al., 2012; Bartels et al., 2012).
Purpose of the Study
The quantitative and cross-sectional study sought to clarify whether there is any
association between T2DM and RA for noninstitutionalized U.S. adults between 1999
and 2012. It explored whether patients with T2DM (independent variable) had increased
prevalence of RA (dependent variable) compared with patients without T2DM using a
U.S. nationally representative sample, both with and without adjustment for potentially
confounding factors. Logistic regression analysis was performed with the complex survey
sampling methods utilizing sampling strata and taking surveys’ weight into consideration
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in order to be generalizable to the U.S. population. To mitigate confounding bias,
covariates identified in the literature as potential confounders (gender, age, race/ethnicity,
education level, and smoking status) were considered in this analysis. The adjusted odds
ratios (ORs) for the association between T2DM and RA were estimated after adjusting
for covariates.
Using a group of patients with RA, this study identified and described potential
characteristics that could differentially affect the prevalence of T2DM. The
characteristics or variables evaluated for this analysis were age, gender, race/ethnicity,
education level, poverty level, disability, smoking status, blood pressure levels, BMI,
lipid levels (high-density lipoprotein [HDL]/ low-density lipoprotein [LDL], total
cholesterol [TC]), CRP, use of antirheumatic medications, and the presence of CVD.
Using a second group of patients with T2DM, this study identified and described
potential characteristics that could differentially affect the prevalence of RA. The
characteristics or variables evaluated for this analysis were age, gender, race/ethnicity,
education level, poverty level, disability, smoking status, blood pressure levels, BMI,
lipid levels (HDL/LDL, TC), presence of CVD, plasma glucose, and glycosylated
hemoglobin (HbA1c).
Using a third group of patients with T2DM and concomitant RA, this study
evaluated and compared the risk of CVD for three groups: T2DM with concomitant RA;
RA without concomitant T2DM; and T2DM without concomitant RA. Logistic
regression was performed to complete these analysis.
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Research Questions and Hypotheses
This study sought to answer the following research questions by testing their
associated hypotheses:
1. Do patients with T2DM have statistically significant increased prevalence of
RA in comparison with patients without T2DM?

H01: Patients with T2DM do not have a statistically significant increased
prevalence of RA compared to patients without T2DM, after adjustment for
potential confounders.

HA1: Patients with T2DM do have a statistically significant increased
prevalence of RA compared to patients without T2DM, after adjustment for
potential confounders.
2. What demographic, lifestyle, or clinical characteristics are significantly
different for those patients with RA and T2DM in comparison with patients
with RA but no presence of T2DM?
Is there a difference in prevalence of RA based on the specific demographic,
lifestyle, or clinical characteristics in patients with and without T2DM?
H02a:
- Patients with T2DM do not have a statistically significant different
prevalence of RA compared to patients without T2DM based on specific
demographic, lifestyle, or clinical characteristics.
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HA2a:
- Patients with T2DM do have a statistically significant different prevalence of
RA compared to patients without T2DM based on specific demographic,
lifestyle, or clinical characteristics.
Characteristics evaluated on this inquiry are demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability,
smoking status, and work functionality), and clinical (blood pressure levels,
BMI, lipid levels [HDL/LDL, TC], CRP, use of antirheumatic medications,
and presence of CVD).
3. What demographic, lifestyle, or clinical characteristics are significantly
different for those patients with RA and T2DM in comparison with patients
with T2DM but no presence of RA?
Is there a difference in prevalence of T2DM based on the specific
demographic, lifestyle, or clinical characteristics in patients with and without
RA?
H03a:
- Patients with RA do not have a statistically significant different prevalence
of T2DM compared to patients without RA based on specific demographic,
lifestyle, or clinical characteristics.
HA3a:
- Patients with RA do have a statistically significant different prevalence of
T2DM compared to patients without RA based on specific demographic,

9
lifestyle, or clinical characteristics.
Characteristics evaluated on this inquiry are demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability,
smoking status, work functionality); and clinical (blood pressure levels, BMI,
lipid levels [HDL/LDL, TC], presence of CVD, plasma glucose, and HbA1c).
4. Do patients with T2DM and concomitant RA have a statistically significant
higher prevalence of CVD in comparison with patients with T2DM and no
presence of RA and patients with RA and no presence of T2DM?
H04a:
- Patients with T2DM and concomitant RA do not have a statistically
significant increased prevalence of CVD compared to patients with T2DM
and no presence of RA and patients with RA and no presence of T2DM, after
adjustment for potential confounders.
HA4a:
- Patients with T2DM and concomitant RA do have a statistically significant
increased prevalence of CVD compared to patients with T2DM and no
presence of RA and patients with RA and no presence of T2DM, after
adjustment for potential confounders.
Theoretical Foundation
This study used a theoretical framework based on the expanded chronic care
model (ECCM) and the social ecological model (SEM). The first model, ECCM, shows
an integrated effort to manage chronic disease, in an organized and multifaceted way, that
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has been proven to work on better management of DM. Social and behavioral
characteristics may also make an important contribution in the association between both
conditions. The second model, SEM, highlight the important of evaluating multiple
factors that could contribute to potential association. This model considers the complex
interplay between individual, relationship, community, societal factors, and public policy.
It helps address the factors that could influence the association between T2DM and RA.
A discussion of these two theories is found in Chapter 2.
Rationale for a connection between DM and RA has been noted in prior research.
First, it is known that cardiovascular risk is higher in both conditions, T2DM and RA.
Second, inflammation plays an important role in both conditions. In RA, the immune
system attacks joints, which creates ongoing inflammation, which in turn, produces
increased markers, such as CRP, and these markers have been shown to be associated
with DM (Schmidt et al., 1999; MacLennan, 2007; Sattar et al., 2003). On the other hand,
inflammation is also associated with insulin resistance, which makes the body less
responsive to insulin, thus increasing the risk of developing T2DM (Schmidt et al, 1999;
Sattar et al., 2003). In addition, some treatments for RA, such as nonsteroidal,
antiinflammatory medications (NSAIDs) and corticosteroids, could elevate blood glucose
levels and thus increase the risk of diabetes; other drugs, such as tumor necrosis factor
(TNF) inhibitors and hydroxychloroquine, are associated with a decreased risk of DM in
patients with RA (Wasko et al., 2011; Antohe et al., 2010; Antohe et al., 2012; Bili et al.,
2011; Solomon et al., 2010b; Solomon et al., 2011; Sasaki et al., 2010; Yokota & Igaki,
2012). A summary of the available data is discussed in the literature review.
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Nature of the Study
This study employed a quantitative, cross-sectional design using a secondary
analysis of data from the large nationally representative data set, the continuous
NHANES. Data analysis was performed using SAS (version 9.2). Different groups from
the diagram in Figure 1 were used to answer the three questions in this study.

T2DM

T2DM/RA
Group 1

NHANES

T2DM/RA (-)
Group 2

T2DM (-)

T2DM (-)/RA
Group 3

T2DM (-)/RA (-)
Group 4

Figure 1. Study cohorts.
For Objective 1, it was aimed to evaluate if patients with T2DM do have a
statistically significant increased prevalence of RA compared to patients without T2DM,
after adjustment for potential confounders. The cross-sectional association between
T2DM and RA was investigated using logistic regression with T2DM as the independent
variable and RA as the dependent variable. A description of variables and crude and
adjusted prevalence of RA for patients with and without T2DM was included. Adjusted
ORs of RA were determined, considering the following potential confounders—age, sex,
race/ethnicity, education, and smoking—as previously determined by Simard and
Mittleman (2007).
For Objective 2, Groups 1 and 3 from the study group diagram (Figure 1) were
used to identify patients with RA and both with and without T2DM. Logistic regression

12
was performed using RA as the dependent variable and T2DM as the independent
variable in order to determine univariate ORs. . This analysis described potential
characteristics that are statistically significantly different comparing prevalence of
T2DM within RA in comparison with prevalence of T2DM within participants with no
presence of RA.. The characteristics evaluated in this inquiry were demographic (age,
gender, race/ethnicity, education level, and poverty level); lifestyle (disability, smoking
status, and work functioning); and clinical (blood pressure levels, BMI, lipid levels
[HDL/LDL, TC], plasma glucose, HbA1c, CRP, and the use of antirheumatic
medications).
For Objective 3, Groups 1 and 2 in the study group diagram were used to identify
patients with T2DM among patients with and without RA. Logistic regression was
performed using T2DM as the dependent variable and RA as the independent variable to
determine univariate ORs. This analysis described potential characteristics that are
statistically significantly different comparing prevalence of T2DM within RA in
comparison with prevalence of T2DM within participants with no presence of RA.
Characteristics evaluated on this inquiry were demographic (age, gender, race/ethnicity,
education level, and poverty level); lifestyle (disability, smoking status, and work
functioning); and clinical (blood pressure levels, BMI, lipid levels [HDL/LDL, TC],
CRP, use of antirheumatic medications, plasma glucose, and HbA1c).
For Objective 4, the analysis described and compared the prevalence rates of
CVD among patients with T2DM and comorbid RA, patients with T2DM and without
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RA, and patients with RA and without T2DM. This analysis included crude and adjusted
prevalence of RA for all groups.
Using NHANES from the National Center for Health Statistics, RA and T2DM
were identified using specific classifications for the target populations:
•

RA: Included all patients 20 years and older with self-reported RA using an
affirmative response to the RA-related question of the survey

•

T2DM: Included all patients 20 years old and older with self-reported
diabetes. To exclude type 1 diabetes mellitus (T1DM), all patients who
reported receiving a physician’s diagnosis before age 30 and who initiated
insulin therapy within one year of diagnosis were excluded. Women reporting
a diagnosis of diabetes during pregnancy were excluded.

The following covariates were evaluated in this study: 1) demographic
characteristics including age, gender, race/ethnicity, education level, and poverty level; 2)
lifestyle characteristics including smoking status, work functioning, and disability; 3)
clinical characteristics including blood pressure levels, BMI, lipid levels (HDL/LDL and
TC); rheumatic-related characteristics including CRP (inflammation) and use of
antirheumatic medications; diabetes-related characteristics including plasma glucose and
HbA1c; and finally presence of CVD.
Definitions
The primary variables and covariates are defined below.
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Primary Variables
Diabetes mellitus (DM): DM is a chronic disease that occurs either when the
pancreas does not produce enough insulin or when the body cannot effectively use the
insulin it produces. Insulin is a hormone that regulates blood sugar. As an effect of DM,
patients suffer hyperglycemia (high blood sugar levels) which leads to serious damage to
different systems of the body. Some of the most common complications of diabetes are
related to damage of the heart, blood vessels, eyes, kidneys, and nerves (USMLM, 2014;
ADA, 2013a). There are different types of diabetes but for this study only T2DM is
considered. T1DM, gestational diabetes (diabetes during pregnancy), and any other type
of diabetes were excluded for the purpose of this study. Pre / bordenline diabetes was not
considered for this analysis. The diagnosis, treatment, and burden of T2DM are discussed
further in Chapter 2.
Rheumatoid arthritis (RA): RA is a chronic, systemic inflammatory disorder that
may affect many tissues and organs, but principally attacks synovial joints. The process
produces an inflammatory response of the synovium (synovitis) secondary to hyperplasia
of synovial cells, excess synovial fluid, and the development of pannus in the synovium.
This process often leads to the destruction of articular cartilage and ankylosis of the
joints. Similar to DM, the cause of RA is unknown, but autoimmunity plays a pivotal role
in both its chronicity and progression. RA is considered a systemic autoimmune disease
that causes the body to produce cells that attack its own tissues. This results in
inflammatory damage to the joints and surrounding muscle resulting in moderate
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discomfort to severe pain, swelling, and redness (CDC, 2012a). The diagnosis, treatment,
and burden of RA are discussed further in Chapter 2.
Covariables
Age: The risk of developing most types of arthritis including RA increases with
age. The risk of T2DM increases with age especially after age 45, which is likely the
result of less exercise, loss of muscle mass, and weight gain as people age.
Gender: Most types of arthritis are more common in women; 60% of all people
with arthritis are women. In general, no significant gender difference has been found for
diabetes.
Race/ ethnicity: Blacks, Hispanics, American Indians, and Asian-Americans are
more likely to develop T2DM than whites. In general, no significant race or ethnic
difference has been found for arthritis.
Education level: Mokdad et.al. (2001) identified that patients with DM having
“less than a high school education” had the highest rate (13%) among the educational
levels. Some literature has indicated that education level is an important marker of
clinical status in RA. Risk factors such as smoking, inactivity, and medication regimen
noncompliance are more prevalent in those patients who have a lower educational level
(high school or less) compared with those classified with a higher education level (more
than high school) (Callahan & Pincus, 1988).
Poverty level: The poverty levels set a minimum amount of gross income a family
needs for food, clothing, transportation, shelter, and other necessities. In the United
States, this level is determined by the Department of Health and Human Services.
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Poverty level varies according to family size. The number is adjusted for inflation and
reported annually in the form of poverty guidelines. Based on data from the Behavioral
Risk Factor Surveillance System (BRFSS), people who make $15,000 or less are three
times more likely to have diabetes than people who make $50,000 or more, regardless of
race. Poverty is an important factor in DM because people with lower incomes are less
able to afford healthy foods, may lack education on good nutrition, or simply have less
access to healthy food options in their particular area. Another point to consider is
inactivity or reduced work functioning, which is higher within patients with diabetes.
Reduced work functioning negatively impact employment, which may lead to lack of
insurance affecting access to medical care. Along the same lines, RA can cause disability
and reduce productivity, which are also associated with unemployment, low poverty
levels and lack of access to medical care (Lundkvist, 2008), .
Smoking: Smoking is a practice in which a substance is burned, and the smoke is
tasted or inhaled. Currently the most common substance is tobacco in the form of
cigarettes. There is plenty of evidence that shows that smoking cigarettes increases the
risk of RA and DM, while quitting can reduce the risk.
Disability: A disability may be physical, cognitive, mental, sensory, emotional,
developmental, or some combination of these. A disability may be present from birth or
occur during a person's lifetime. The consequences of disability are extensive including
increased absenteeism, lack of employment, lower income levels, limited access to health
care services, decreased health status, and lower quality of life. Arthritis and other
rheumatic conditions are the most common cause of disability among U.S. adults and
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have been for the past 15 years (CDC, 2013a). Forty-two percent of adults with doctordiagnosed arthritis report arthritis-attributable activity limitations (CDC, 2010b).
The NHIS has found that disability affects an estimated 20–50% of patients with
diabetes including work disability. Patients with diabetes, in general, report rates of
disability that are substantially higher than those reported by the general U.S. population
(CDC, 2006; Mayfield, 1999; Aubert, R.,1995).
Blood pressure levels and hypertension: Blood pressure is the pressure of the
blood within the arteries. It is produced primarily by the contraction of the heart muscle.
Systolic blood pressure (SBP) is defined as the highest arterial blood pressure of a cardiac
cycle occurring immediately after the contraction of the left ventricle of the heart and
diastolic blood pressure (DBP) is the lowest arterial blood pressure of a cardiac cycle
occurring during passive rhythmical expansion of the heart. Its measurement is recorded
by two numbers, and measurements are reported in millimeters of mercury (mmHg).
Hypertension: Hypertension is the elevation of blood pressure.
The following table reflects blood pressure categories defined by the American
Heart Association (AHA).
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Blood pressure
category

Systolic
mm Hg (upper #)

Diastolic
mm Hg (lower #)

Normal

less than 120

and

less than 80

Prehypertension

120 – 139

or

80 – 89

High blood pressure
(hypertension) Stage 1

140 – 159

or

90 – 99

High blood pressure
(hypertension) stage 2

160 or higher

or

100 or higher

Hypertensive crisis
(emergency care needed)

Higher than 180

or

Higher than 110

There is evidence in the literature that has indicated an association between
hypertension and diabetes as well as its complications including micro- and
macrovascular disease. RA, as well as DM, is associated with elevated risk of CVD,
which is attributed to several potential factors including hypertension. Hypertension is
highly prevalent and seems to be underdiagnosed and undertreated among patients with
RA (Panoulas et al., 2008).
BMI, obesity, and overweight: BMI is defined as the individual's body weight
divided by the square of his or her height. Thisuniversal formulaused in medicine
produces a unit of measure of kg/m2.
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The CDC uses the following weight categories for adults based on BMI (body
mass index) ranges.
Weight status

BMI

Underweight Below 18.5
Normal
18.5 – 24.9
Overweight
25.0 – 29.9
Obese
30.0 and above
Obesity is a medical condition that is characterized by excessive accumulation
and storage of fat in the body and is considered an independent risk factor for several
chronic conditions including T2DM, RA, and CVD. Carrying excess pounds puts stress
on joints, particularly on the knees, hips, and spine. Obese people have a higher risk of
developing arthritis. Being overweight is a primary risk factor for T2DM. The more fatty
tissue a person has the more resistant to insulin the cells become (AHA, 2013).
Lipid levels (HDL/LDL and TC): Blood lipids (or blood fats) are lipids in the
blood, either free or bound to other molecules. They are mostly transported in a protein
capsule, and the density of lipids and type of protein determine the fate of the particle and
its influence on metabolism. The concentration of blood lipids depends on intake and
excretion from the intestine, and uptake and secretion from cells. Blood lipids are mainly
fatty acids and cholesterol. Hyperlipidemia is the presence of elevated or abnormal levels
of lipids and/or lipoproteins in the blood and is a major risk factor for CVD.
The 2001 National Cholesterol Education Program (NCEP) clinical guidelines for
cholesterol testing and management are as follows:
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Classification

Total cholesterol

Normal blood cholesterol

<200 mg/dl

Borderline-high cholesterol

200–239 mg/dl

High cholesterol

>240 mg/dl

HDL and LDL are two smaller of the five major groups of lipoproteins, which
enable lipids like cholesterol and triglycerides to be transported within the water-based
bloodstream.
In healthy individuals, about 30% of blood cholesterol is carried by HDL. Having
large numbers of large HDL particles correlates with better health outcomes, and hence
HDL is commonly called "good cholesterol." In contrast, having small amounts of large
HDL particles is independently associated with atheromatous disease progression within
the arteries. Studies have shown that higher levels of type-B LDL particles (as opposed to
type-A LDL particles) promote health problems and CVD, and hence LDL is commonly
called “bad cholesterol.”
C-reactive protein (CRP): CRP is a protein found in the blood, levels of which
rise in response to inflammation. Measuring CRP level is a screen for infectious and
inflammatory diseases. Rapid, marked increases in CRP occur with inflammation,
infection, trauma and tissue necrosis, malignancies, and autoimmune disorders. Because
there are a large number of disparate conditions that can increase CRP production, an
elevated CRP level does not diagnose a specific disease. An elevated CRP level can
provide support for the presence of an inflammatory disease, such as RA.
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Use of Antirheumatic medications: A variety of medications is used to treat RA.
When given early enough, some interrupt the progression of the disease by reducing
inflammation and preventing joint damage. Others help relieve symptoms of joint
stiffness and pain. The following drugs can be given alone or in combination: diseasemodifying anti-rheumatic drugs (DMARDs); biologic response modifiers (a category of
DMARDs); glucocorticoids; NSAIDs; and analgesics.
Plasma glucose: Glucose is the primary sugar that is made from the foods and
beverages a person consumes. This glucose travels throughout the bloodstream to provide
energy to cells in all regions of the body. Plasma glucose refers to the amount of this
primary sugar that is found in the liquid portion of the blood. The fasting plasma glucose
(FPG) test measures blood sugar levels and is one of the alternatives used to diagnose
diabetes. This is a relatively simple and inexpensive test that identifies problems with
insulin function. Measurements of plasma glucose are reported in milligrams per deciliter
(mg/dL) or millimoles per liter (mmol/L).
General glucose targets specified in guidelines for management of T2DM in the
United States are shown in the following table:
HbA1c

FPG

Postprandial
glucose

Guideline
authority

Reference

≤6.5%

<110 mg/dL)

≤180 mg/dL)

AACE

Garber et
al., 2013

<11.1
mmol/L
ADA
ADA 2014
(<200 mg/dL)
Note: AACE = American Association of Clinical Endocrinologists; ADA = American
Diabetes Association.
Plasma glucose is also important to identify episodes of hypoglycemia or low
<6.5%

<7 mmol/L
(<126 mg/dL)

level of blood sugar, defined as blood glucose level lower than 70 mg/dL.
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Glycated hemoglobin or glycosylated hemoglobin (hemoglobin A1c, HbA1c,
A1C, or Hb1c): This is a form of hemoglobin that is measured primarily to identify the
average plasma glucose concentration over prolonged periods of time. It is formed in a
nonenzymatic glycation pathway by hemoglobin's exposure to plasma glucose. Normal
levels of glucose produce a normal amount of glycated hemoglobin. As the average
amount of plasma glucose increases, the fraction of glycated hemoglobin increases in a
predictable way. This serves as a marker for average blood glucose levels over the
previous months prior to the measurement.
The 2010 American Diabetes Association (ADA) Standards of Medical Care in
Diabetes added the HbA1c ≥ 48 mmol/mol (≥6.5%) as another criterion for the diagnosis
of glucose levels. High levels of HbA1c have been associated with CVD, nephropathy,
and retinopathy. Monitoring HbA1c in patients with diabetes may improve outcomes. In
general, the reference range (that is found in healthy people) is about 20 to40 mmol/mol
(4–5.9%). The International Diabetes Federation and American College of Endocrinology
recommend HbA1c values below 48 mmol/mol (6.5%) while American Diabetes
Association recommends HbA1c values below 53 mmol/mol (7.0%) for most patients.
Cardiovascular disease (CVD): CVD is a group of disorders of the heart and
blood vessels and include coronary heart disease: disease of the blood vessels supplying
the heart muscle; cerebrovascular disease: disease of the blood vessels supplying the
brain; peripheral arterial disease: disease of blood vessels supplying the arms and legs;
rheumatic heart disease: damage to the heart muscle and heart valves from rheumatic
fever, caused by streptococcal bacteria; congenital heart disease: malformations of heart
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structure existing at birth; deep vein thrombosis and pulmonary embolism: blood clots in
the leg veins, which can dislodge and move to the heart and lungs. Heart attacks and
strokes are usually acute events and are mainly caused by a blockage that prevents blood
from flowing to the heart or brain. The most common reason is a build-up of fatty
deposits on the inner walls of the blood vessels. Strokes can be caused by bleeding from a
blood vessel in the brain or by blood clots.
There are several studies that provide evidence of the increased cardiovascular
risk in RA and DM. For RA, studies have found 1.5 to 2-fold increase in comparison with
the general population. Potential reasons are risk factors associated with CVD as well as
RA such as obesity, insulin resistance, hypertension, atherosclerosis, dyslipidemia
(Stamatelopoulus et al., 2009b ), and inflammation (Sattar et al., 2003). Cardiovascular
risk in RA is increased to an extent comparable to the risk found in DM (Van Halm et al.,
2009; Lindhardsen et al., 2010; Peters et al., 2009; Stamatelopoulos et al., 2009a). CVD
has been identified as the major complication of DM and is the primary cause of early
mortality among people with this condition. About 65% of patients with DM die from
heart disease and stroke. Adults with DM are two to four times more likely to have heart
disease or suffer a stroke than people without diabetes (NIH, 2007; CDC, 2011a). This
was confirmed by a meta-analysis of 102 prospective studies in which it was concluded
that patients with DM have about two-fold excess risk for a wide range of vascular
diseases, independently from other conventional risk factors (Sarwar, 2010).
Sample weight: A fraction or selection of individuals from within a statistical
population is used to estimate characteristics of the whole population. A sample weight is
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used when a sample design does not give each individual an equal chance of being
selected. In this case, each person is assigned with a sample weight to compensate for the
unequal selection probability (e.g., for minority racial/ethnic population groups) and
adjust for nonresponse. This strategy is used by NHANES to avoid bias when
determining estimates of a nationally represented sample.
Assumptions
The sample used in NHANES was selected to represent the adult U.S. population.
The information on the set of surveys utilized for the current study was collected in a
consistent and appropriate manner by health care providers and interviewers. It is
expected that all information collected in the survey is kept strictly confidential.
NHANES is an ongoing program and the information collected contributes to annual
estimates. Due to this reason, it is appropriate to accumulate data over several years to
provide adequate estimates. It was assumed that the criteria selected to define T2DM and
RA were accurate for both conditions, and data self- reported by patients was true.
Scope and Delimitations
The current study used data from the continuous NHANES to evaluate the
association between T2DM and RA. The NHANES population represented a weighted,
random sample of the civil, noninstitutionalized population of the United States. It is
important to document that the population sample and the limitations of the database
were applicable to the U.S. population and may have excluded generalizations (external
validity) to other countries, especially with different health care systems. NHANES data
captures one point in time (cross-sectional design), which provides almost no basis for
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drawing conclusions about causality; thus, this study can be used only for correlation
purposes. Additional prospective and longitudinal studies will be needed if a correlation
is found in order to demonstrate causality between variables.
Limitations
The NHANES study does not have a specific question to determine the type of
diabetes a patient has. Diabetes for the current study included any patient with T2DM
based on patient’s self-reported diabetes. To eliminate potential patients with T1DM, all
patients who reported receiving a physician’s diagnosis before age 30 and who initiated
insulin therapy within 1 year of diagnosis were excluded. There is a small chance of
misclassification which could over or underestimate the prevalence of T2DM. Women
with a diagnosis of diabetes during pregnancy or evidence of gestational diabetes were
excluded.
The design of this study has various limitations. First, due to the cross-sectional
design, analysis was restricted to the association between DM and RA; no temporality or
causality information, can be concluded. Second, both T2DM and RA have a high
prevalence in the older population, which could bias prevalence. Adjustment by age was
intended to mitigate this possibility.
The process of identifying diabetes and arthritis in the database could have lead to
misclassification, considering the self-reporting from patients, which is considered
another limitation. Someaspects of subject recruitmentcould erve to underestimate the
prevalence of the disease in the population. For example, participants with severe disease
in both cases could be missed because they were physically unable to see a doctor for
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examination; along the same line, institutionalized people (e.g., those in nursing homes)
are excluded from NHANES. In addition, patients without access to health care or those
who were economically disadvantaged may not have had the opportunity to be diagnosed
for conditions that require a specialist. Disability could also have minimized the number
of patients considered for this survey.
Significance
Diabetes is a broadly recognized public health issue and, as part of a public health
strategy to improve health, it is important to consider all related health issues and to
investigate them in a interdisciplinary manner (ADA, 2013a; ADA, 2013b; ADA, 2014).
RA is not widely recognized as a comorbidity of diabetes and thus is not managed as
such (CDC, 2012a).
Among individuals with diabetes, comorbid RA might present an under
recognized hurdle and at the same time is not managed as part of the potential difficulties
that people may encounter when managing diabetes.
This study has implications for social change. This resulting data may give health
care providers and patients a better understanding of how to manage both conditions
using an interdisciplinary approach. Results may also support the creation of adequate
public health interventions for preventing arthritis in patients with diabetes and for
managing modifiable lifestyle characteristics for both conditions.
Summary
Data from the CDC indicates that more than 50% of all people in the United
States with diabetes mellitus (DM) have some kind of arthritis (CDC, 2008). However,
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there is no recognized association between T2DM and RA and for this reason these two
conditions are not managed in a interdisciplinary manner.. The current study aimed to
identify if any association existed between T2DM and RA for noninstitutionalized U.S.
adults between 1999 and 2012 using a nationally representative sample from the
NHANES. A quantitative, cross-sectional investigation was used to determine if patients
with T2DM had increased prevalence of RA. At the same time, the current study sought
to clarify which characteristics could differentially affect the association between both
groups and the potential risk increased risk for of CVD when this comorbidity exists.
With the complex survey methodology in mind, a logistic regression analysis was
performed taking the complex survey methodology into consideration to analyze the U.S.
population. The prevalence and adjusted odds ratios (OR) for the cross-sectional
association between T2DM and RA was determined after adjusting for potential
confounders. The study may provide patients and health care providers with a better
understanding of how to manage both conditions in a interdisciplinary manner.
Chapter 1 introduced the problem along withthe approach for answering the
research question. Chapter 2 provides an overview of the relevant literature. Chapter 3
includes a detailed description of the research methods. The results are discussed in
Chapter 4. A summary of findings, conclusions, and recommendations for future
investigation is included in Chapter 5.
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Chapter 2: Literature Review
Introduction
The purpose of this chapter is to define the main variables for this investigation,
DM and RA. In the first section of this chapter, the definition, diagnosis, burden, and
treatment of DM and RA are discussed . Second, a description of the theoretical
foundations and how they inform the current research are covered. Finally, the available
research on DM and RA are discussed, including the following: the risk of CVD in both
conditions; studies evaluating inflammation and markers of inflammation; research on the
behavioral aspects of this issue; and a discussion of the few available studies that were
developed in order to evaluate the association between DM and RA—the ultimate target
of the literature review.
RA and DM are both disorders with unknown causality and similar risk factors.
The association between these two conditions has not been clearly defined. Some studies
on this association lack consistency or conclusions. The majority of the results found in
the literature were based on studies that were not designed to assess this relationship. As
indicated by Doran (2007), it is not clear whether there is an increased prevalence of DM
in patients with RA or an increased prevalence of RA in patients with DM. This study
sought to evaluate the cross-sectional association between T2DM and RA and to identify
the characteristics that may be relevant in this association. This literature review will
provide an overview of the effort that has been done in this area..
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Literature Review Strategy
The following databases—limited to full text from 2008 to 2012—were used for
the literature review: MEDLINE, EMBASE, ProQuest (dissertations) and Cochrane
Collaborative. The keywords were limited to diabetes and rheumatoid arthritis. Seminal
review articles were read when they offered reference lists to key articles. To avoid
publication bias, three supplementary sources were used over the same time period to
identify relevant articles: American Diabetes Association (ADA), European Association
of the Study of Diabetes (EASD) and International Diabetes Foundation (IDF).
The following criteria were followed to select articles: (a) information was
pertinent to any one of the research questions; (b) a full-text article was available and
included a full description of the study design and methods used to assess the association
between main variables; (c) the publication was available in English or Spanish; (d)
general articles on T2DM or DM were included (all other specific types of DM were
excluded); and (e) arthritis was limited to RA.
Diabetes Mellitus
Diabetes is a group of metabolic diseases characterized by hyperglycemia
resulting from defects in insulin secretion, insulin action, or both. The chronic
hyperglycemia (high levels of glucose in blood) of diabetes is associated with long-term
damage, dysfunction, and failure of different organs including retinopathy (damage of the
eyes), nephropathy (damage to the kidneys), neuropathy (issues with nerves), and CVD
(problems with heart and blood vessels) (ADA, 2013a; UKPDS, 2000). There are
different types of diabetes but for this study only T2DM is considered. T1DM,
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gestational diabetes (diabetes during pregnancy), and any other type of diabetes will be
excluded for the purpose of this study. Prediabetes will not be considered in this analysis.
The most common symptoms for diabetes are polyuria (excessive excretion of
urine), polydipsia (continuous thirst), constant hunger, weight loss, vision changes, and
fatigue. Symptoms are similar in all types of diabetes, but they are less marked in T2DM,
which makes the disease difficult to diagnose. This delay on diagnosis may have critical
consequences because the disease could exist for several years affecting systems in the
body before awareness of the disease. T2DM was an adult disease until recently, but it is
now also occurring in children due to changes in lifestyles and behaviors during the last
decades.
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Diagnosis of Diabetes
The ADA issued diagnostic criteria for DM based on one of four abnormalities:
HbA1c, FPG, random elevated glucose with symptoms, or abnormal oral glucose
tolerance test (OGTT) (ADA, 2013a).
Specific criteria for the diagnosis of diabetes are as follows:
1. HbA1c ≥6.5%. The test should be performed in a laboratory using a
method that is National Glycohemoglobin Standardization Program
(NGSP) certified and standardized to the Diabetes Control and
Complications Trial (DCCT) assay.*
Or
2. FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for
at least 8 hours.*
Or
3. 2-hours plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The
test should be performed as described by the WHO, using a glucose load
containing the equivalent of 75 g anhydrous glucose dissolved in water.*
Or
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic
crisis, a random plasma glucose ≥200 mg/dl (11.1 mmol/l).
* In the absence of unequivocal hyperglycemia, Criteria 1–3 should be confirmed
by repeat testing.
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Classifications of Diabetes
There are four classifications of diabetes: (a) T1DM; (b) T2DM; (c) gestational
diabetes, and d) other. The first two categories include the vast majority of all patients
with diabetes considering approximately 90–95% for T2DM and 5–10 % for T1DM.
T2DM will be the main focus of this investigation. T1DM, gestational diabetes, and other
types of diabetes are not included in the literature review for the purpose of this study.
Type 2 Diabetes Mellitus
This type of diabetes formerly called noninsulin-dependent or adult-onset is the
most common among all cases with diabetes and includes individuals who have insulin
resistance and usually have relative (rather than absolute) insulin deficiency. T2DM is a
chronic condition in which insulin resistance disturbs the body’s ability to properly
metabolize carbohydrate, fat, and protein preventing the cells in the body from effectively
accessing and utilizing blood glucose as a source of energy (CDC, 2013b; Ryden et al.,
2007). This type of diabetes is a progressive disease that worsens with elevated blood
glucose levels, and is a consequence of genetic predisposition, unhealthy diet, physical
inactivity, and increasing weight (CDC 2013b; Ryden et al., 2007). There are many
different causes of this form of diabetes, but the specific etiologies are not known. In
these patients, autoimmune destruction of cells does not occur, and most patients are
obese, and obesity itself causes some degree of insulin resistance. Patients who are not
obese by traditional weight criteria may have an increased percentage of body fat
distributed predominantly in the abdominal region. This form of diabetes frequently goes
undiagnosed for many years because the hyperglycemia develops gradually, and at earlier
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stages is often not severe enough for the patient to notice any of the classic symptoms of
diabetes. T2DM symptoms may develop very slowly. In fact, a patient can have T2DM
for years without knowing it, which increases the risk of developing micro- and macro
vascular complications. The risk of developing T2DM increases with age, obesity, and
lack of physical activity (ADA, 2013a).
Treatment of Diabetes
The 2009 Consensus Statement from the ADA and the EASD recommends that
all diabetes management programs include, at diagnosis and throughout the management
of T2DM, a lifestyle intervention strategy to promote weight loss and increase activity
levels (Nathan et al., 2009). Such lifestyle programs, however, generally have limited
long-term success in maintaining glycemic goals in patients with T2DM, thus requiring
the need for medications to control glucose levels. Medications available to control
diabetes are the following:
•

Oral antidiabetic medications: biguanides (e.g., metformin); secretagogues
(e.g., sulphonylureas); thiazolidinediones (e.g., glitazones); alphaglucosidase inhibitors; meglitinides (e.g. repaglinide); dipeptidyl
peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, vildagliptin); and sodium
glucose co-transporter-2 (SGLT-2) inhibitors (e.g., canagliflozin,
dapagliflozin)

•

Insulin: short-acting and rapid-acting (mealtime) insulin therapies;
intermediate-acting and long-acting (basal) insulin therapies; and mixed
insulin therapies
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•

Glucagon-like peptide-1 (GLP-1) analogs

Burden of Diabetes
The burden of diabetes is increasing globally, particularly in developing countries.
The IDF estimated that approximately 371 million people worldwide have diabetes
(including T1DM or T2DM) as of 2012. The number of cases is expected to grow to 552
million by the year 2030 (IDF, 2012). Diabetes increases the risk of cardiovascular and
cerebrovascular disease. The risk of dying as a result of CVD in people with diabetes
(primarily heart disease and stroke) is more than 50%. The overall risk of dying among
people with diabetes is at least double the risk of people without diabetes (WHO, 2013a).
In the United States, diabetes affects 29.1 million people of all ages which
constitute approximately 9.3% of the population. In 2010, diabetes was the seventh
leading cause of death; and based on death certificate reports, diabetes contributed to
234,051 deaths in the United States (CDC, 2014).
Several important studies contributed to a greater understanding of DM and the
implications of this condition including the DCCT, UK Prospective Diabetes Study
(UKPDS), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE), and Action to Control Cardiovascular Risk
in Diabetes (ACCORD):
•

The DCCT is a major clinical study conducted from 1983 to 1993 funded
by the National Institute of Diabetes and Digestive and Kidney Diseases.
The study showed that maintaining blood glucose levels as close to normal
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as possible is associated with a decrease of micro- and macrovascular
complications (DCCT, 1993; DCCT, 1996).
•

The UKPDS is the largest randomized, multicenter trial for newly
diagnosed patients with T2DM conducted from 1977 to 1997 in 23 UK
clinical sites. This study concluded that a better control of blood glucose
and/or blood pressure is associated with a reduction of diabetes
complications. The results of this study indicated that improving glycemic
control reduces the risk of microvascular disease by 25% (p<0.05).
(UKPDS, 2000).

•

The ADVANCE study suggests that a strategy of intensive glucose control
may reduce the occurrence of micro- and macrovascular events, as
patients in this study who received treatment targeting intensive control of
glucose levels (HbA1c level < 6.5%) experienced a 10% relative reduction
in the occurrence of major macro- and microvascular events (Patel et al.,
2008).

Other studies, including the ACCORD study, that were presented at the ADA
conference in 2008 conference have suggested that intensive control of blood glucose
levels in T2DM might have no impact on the likelihood of death or CVD, or may even
increase the risk of cardiovascular events and mortality. The ACCORD study concluded
that the use of intensive therapy increased mortality and did not significantly reduce the
occurrence of major cardiovascular events (Gerstein et al., 2008; Genuth & Ismail-Beigi,
2012).
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Diabetes prevalence is increasing dramatically worldwide. The following factors
are some of the causes for the elevated numbers: changes in lifestyle including poor
nutrition and inactivity; demographic changes such as aging, which increase the high risk
population; and better surveillance and interventions, which identify more cases
(USDHHS, 2013). Diabetes is an important public health challenge but also has big
implications on the economic aspect of health management. Based on the last analysis
from the ADA, the estimated cost of diagnosed diabetes in 2012 is $245 billion,
considering direct medical costs ($176 billion) and lack of productivity ($69 billion). The
cost of diabetes care accounts for more than one in five health care dollars in the United
States (ADA, 2013b, CDC, 2011a).
Rheumatoid Arthritis
RA is a chronic disease identified by inflammation including joint swelling, joint
tenderness, and destruction of synovial joints, which lead to severe disability and
premature mortality (Aletaha et al., 2010). It is an autoimmune disease, which means the
body's immune system mistakenly attacks healthy tissue, and its cause is unknown. RA
can occur at any age; however, it is more common in middle age. Women get RA more
often than men. Infection, genes, and hormone changes may be linked to the disease.
RA usually affects joints on both sides of the body equally. Wrists, fingers, knees,
feet, and ankles are the most commonly affected. The disease often begins slowly,
usually with only minor joint pain, stiffness, and fatigue. One of the most common
symptoms is morning stiffness, which could last more than one hour. In addition, joints
may feel warm, tender, and stiff when not used for an hour. Joint pain is often felt on the
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same joint on both sides of the body. Over time, joints may lose their range of motion and
may become deformed. Other symptoms include chest pain when taking a breath
(pleurisy); dry eyes and mouth (Sjogren syndrome); burning eyes, itching, and discharge;
nodules under the skin (usually a sign of more severe disease); numbness, tingling, or
burning in the hands and feet; and sleep difficulties.
Diagnosis of Rheumatoid Arthritis
There is no specific test that can confirm a diagnosis of RA. Most, but not all,
patients with RA will have some abnormal test results. Two lab tests that often help in the
diagnosis are: a) rheumatoid factor test; and b) anti-CCP antibody test. Other tests that
may be done include: complete blood count; CRP; erythrocyte sedimentation rate; joint
ultrasound or magnetic resonance imaging (MRI); joint x-rays; and synovial fluid
analysis.
Treatment of Rheumatoid Arthritis
The key objectives when treating RA are to reduce pain, control inflammation,
and delay or stop the progression of the disease. The treatment of RA is more than just
medications--it a multifaceted group of elements including medications, occupational or
physical therapy, exercise, and in some cases, surgery. It is important to identify the
disease as early as possible and treat it aggressively to delay or stop the progression of
joint damage.
The following treatments are commonly used for RA: NSAIDs; DMARDs;
biologics; and steroids to treat severe RA or when symptoms flare. Surgery (joint
replacement) is an option when joint pain and inflammation become intolerable or joints
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simply refuse to function. NSAIDs reduce pain and inflammation but do not slow
progression of RA. DMARDs help slow or stop the progression of disease by suppressing
the immune system overall, but there is an increased probability of infection.
The newest and most effective treatments for RA are biologics that are genetically
engineered proteins. They are designed to inhibit specific components of the immune
system that play a pivotal role in inflammation, which is a key component in this
condition. Biologic drugs are commonly used when previous drugs have failed to stop the
inflammation of RA. It has been found that biologics may slow or even stop RA
progression; however because biologics suppress the immune system, they also increase
the risk of infection.
As previously mentioned for severe RA or when RA symptoms flare, steroids
may be an option to ease the pain and stiffness of affected joints. They can be given as
injections directly into an inflamed joint or can be taken as a pill. Potential side effects of
long-term steroid use include high blood pressure, osteoporosis, and diabetes.
Burden of Rheumatoid Arthritis
The majority of population-based descriptive statistics on RA is available because
of the Rochester Epidemiology Project (REC). REC was originally funded by the
National Institute of General Medical Sciences in 1966 under the direction of Dr.
Leonard T. Kurland. Based on this study, in 1995-2007, 41 per 100,000 people were
diagnosed with RA each year. Incidence rose with age (e.g., 8.7 per 100,000 people
among those aged 18-34 compared with 54 per 100,000 among those aged ≥ 85 years);
and incidence peaked among people aged 65-74 years (89 per 100,000) (all estimates
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age-adjusted to 2000 U.S. population). The prevalence of RA is believed to range from
0.5–1.0% in the general population. Prevalence estimates derived from 2001-2005 U.S.
ambulatory health care system data estimated that 1.5 million U.S. adults have RA. The
age-adjusted prevalence of RA among women was 7.7 per 1000 compared with 4.4 per
1000 among men (CDC, 2012a).
RA causes significant morbidity, disability, and mortality but also substantially
decreases quality of life and productivity, which negatively impacts society as well as
individual patients. RA impacts people of all ages but most heavily on people of working
age (disease is most common after 40), and it is a major cause of sickness, absence,
disability, and unemployment.
Similar to DM, RA has big economic implications for the population. Based on
available literature, the total annual cost of RA in the United States is around $19.3
billion. According to Birnbaurm et al. (2010), 33% of the total cost is allocated to
employers, 28% to patients, 20% to the government, and 19% to caregivers. Adding
intangible costs of quality-of-life deterioration ($10.3 billion) and premature mortality
($9.6 billion), total annual societal costs of RA (direct, indirect, and intangible) increased
to $39.2 billion (Birnbaum et al., 2010).
Theoretical Foundation
This study has a theoretic foundation based on the ECCM and the SEM. The first
model shows an integrated effort to manage chronic disease using an organized and
multifaceted approach that has been proven to improve management of DM and the
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second one draws an important evaluation of multiple factors or characteristics that could
contribute to the potential association.
Expanded Chronic Care Model
The ECCM was developed in 2003 by Barr et al. to improve the original model
called ChroniccCare model (CCM). CCM was created by Dr. E. Wagner in 1996, in the
United States, to support the care of patients with chronic disease and combine a number
of approaches to improve the overall management of the diseases. This model provides a
broader approach to the prevention and management of chronic diseases and focuses
practice and efforts toward health outcomes for individuals, communities, and
populations (Barr et al., 2003).
The original model combines elements of health promotion and population health
including
•

Self-Management – Implementing various approaches to enhance skills
and capacities for personal health and wellness. Individuals are offered
support by their health care provider and in the community to develop
skills to improve their health.

•

Decision Support – Using guidelines and standards to guide health care
services. Health care providers use specific information to make
appropriate decisions about health care and disease management.

•

Delivery System Design – Organizing and coordinating health care
services in ways that meet the needs of individuals to better prevent and
manage chronic disease.
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•

Information Systems – Developing systems to collect information about
health. The information can be used to make the case for new policies and
programs, evaluate established programs, and support new ways of
working to improve the quality of care.

The new model is integrated with the following components:
•

Health System - Organization of Healthcare - Program planning that
includes measurable goals for better care of chronic illness.

•

Community Resources and Policies - Developing partnerships with
community organizations that support and meet patients' needs.

Figure 2 and 3 includes figures 1 and 2 from Barr et al., 2003 to clearly show the
enhancement of the model.

Figure 2. The chronic care model (reprinted with permission from Longwoods Publishing
Corporation).
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Figure 3. The expanded chronic care model (reprinted with permission from Longwoods
Publishing Corporation).
The model is organized and brings multifaceted support for primary care teams
that have been proven to positively affect care of patients with diabetes (Coleman et al.,
2009; Nutting et al., 2007). The expanded version of the model incorporates other areas
like population health promotion, recognition of the social determinants of health, and
enhanced community participation, which bring a better management of chronic diseases
(Barr et al., 2003).
Chronic disease is a major threat to the health of a population; this group of
diseases is the most common cause of death and the most costly element to the health
care system (WHO, 2013b). There are several factors contributing to the elevated
prevalence of chronic disease including the high rates of modifiable risk factors, such as
smoking, physical inactivity, unhealthy diets, and excess alcohol use. These risk factors
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drive other intermediate risk conditions, such as high blood pressure, high blood sugar,
excess body fat, and high blood cholesterol. In addition, mental and emotional stress may
be important aspects in the development or progression of chronic disease. The age of the
population is another point to consider in this topic because chronic diseases become
more prevalent as people get older. There are many other factors that affect health
including income level, education level, and employment status. It is clear that social,
behavioral, economic, and environmental conditions influence a person’s ability to
maintain good health, prevent chronic disease, and manage the complications of the
disease. Good health is necessary to maintain the labor force and to continue the wellbeing of individuals and the continued wealth of the world (Sullivan, S.,2011).
In order to better manage this hazard, a comprehensive and coordinated approach
must be implemented to prevent complications and better manage progression of disease,
which includes
•

All parties working together, including individuals, the community, and
health care providers (interdisciplinary approach)

•

Support of individuals to become more engaged and active in managing
their own health (better understanding of diseases and potential
interactions between them to better manage health in general)

•

Use of the most current evidence and guidelines to provide quality care in
a coordinated, team-based approach with many disciplines working
together (use current and correct information and standards to provide
quality care)
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•

An increased focus on promoting health and preventing disease and the
progression of disease

This model tries to achieve optimal health considering all of the determinants of
health for chronic disease prevention and management. As previously explained in
Chapter 1, association between T2DM and RA has not been demonstrated. The results of
this study are essential to achieve different components of the model including selfmanagement, interdisciplinary decision support, and delivery system to manage both
chronic conditions (T2DM and RA) investigated in this research. Regardless of advances
in treatment, research shows that patients frequently do not achieve targets nor get the
care they want or need, thus a different approach is needed to achieve better outcomes
(Sullivan, 2011).
This investigation intends to provide a better understanding of the association
between T2DM and RA, which will help health care providers to incorporate it in their
daily care practice but also will inform patients, health care systems, and government if
action may be needed in this area. If appropriate, new guidelines or interventions could
be created to better manage both conditions in a interdisciplinary approach and integrated
decision support and to improve health outcomes as recommended per the model. This
study will also describe characteristics that could be relevant for this association which
will create the foundation for areas of intervention.
It has been well documented that this approach has been successful when applied
to diabetes management (Vargas et al., 2007; Frei et al., 2010). Coleman et al. (2009)
examined the evidence of this model’s effectiveness by reviewing articles published since
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2000 that used one of five key CCM papers as a reference. This review found that these
studies suggest that redesigning care using the CCM leads to improved patient care and
better health outcomes. Vargas et al. indicated that patients with diabetes experienced
reduced risk of CVD; for every 48 patients who received care from a practice using this
model, risk declined by one CVD event (Vargas et al., 2007). Other quality improvement
evaluations based on the CCM have been published. All showed improvement on some
process measures, and most also showed improvement on some intermediate outcome
measures such as HbA1c, LDL cholesterol, and arterial pressure. The authors indicated
that due to limitations in the study designs of these evaluations, it is difficult to conclude
that these changes are the result specifically from CCM efforts.
It is clear that social, behavioral, and environmental conditions influence a
person’s ability to maintain good health, prevent chronic disease, and manage the
complications of the disease. These characteristics may also have an important
contribution in the association between both conditions (T2DM and RA). This leads to
the second model contemplated in this research, which is the Social Ecological Model
(SEM).
Social Ecological Model
This SEM was introduced in 1970s, formalized as a theory in the 1980s, and
continually revised by Urie Bronfenbrenner. This model considers the complex interplay
between individual, relationship, community and societal factors, and public policy.
The application of the SEM focuses on several goals: to explain the personenvironment interaction, to improve people-environment transactions, to encourage
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human growth and development in particular environments, and to improve
environments, so they support expression of individual’s system’s natures. Knowing
appropriate information to prevent illnesses or complications or to increase benefit, for
example, a person should avoid an environment in which they may be more susceptible
to have negative outcomes or try to incorporate some settings that are particularly
conducive to a positive outcome or health benefits.
The SEM looks at multiple levels of influence on specific health behaviors
including the following: individual, relationship, community and societal factors, and
public policy (see Figure 4)
•

Individual – Intrapersonal--individual's knowledge, demographics,
attitudes, values, skills, behavior, self-concept, self-esteem

•

Relationship – Interpersonal--social networks, social supports, families,
work groups, peers, friends, neighbors norms, incentives, organizational
culture, management styles

•

Community/Society--community resources, organizational structure,
communication networks, neighborhood organizations, folk practices,
nonprofit organizations, informal and formal leadership practices

•

Public policy--legislation, policies, taxes, regulatory agencies, laws

Indivudual

Relationship

Figure 4. Social ecological model levels.

Community / Society

47
Multi-level interventions are considered the most effective in changing behavior.
This investigation will help define and describe characteristics that could be relevant in
the association between DM and RA. For diabetes, self-management education has been
identified as “the cornerstone of care for all individuals with diabetes who want to
achieve successful health-related outcomes” per the ADA and the National Standards for
Diabetes Self-Management Education (Messing et al., 2004, page S143).
An ecological approach to self-management not only includes the individual but
also integrates the patient characteristics with the services and support they receive from
their social situation, which includes family, friends, worksites, organizations, and
cultures; and the physical and policy environments of neighborhoods, communities, and
governments. From this perspective, the individual should be aware of factors that help
them with the initiation and maintenance of healthy behaviors or environments that
improve health outcomes.
The current investigation in this document may identify and describe all potential
characteristics relevant in the association between T2DM and RA. Social and behavioral
characteristics to be evaluated in this case are race/ethnicity, education level, poverty
level, disability, smoking status, and work functionality. The results from the study will
enhance the understanding of these characteristics for RA and T2DM patients and the
relationship to the potential association. Results of this investigation may be used as the
foundation for future diabetes programs to facilitate potential interventions for patients
with RA and T2DM.
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Previous Research
In addition to the theoretical foundation discussed before, prior research also
alluded to rationale that could connect DM and RA. First, it is known that cardiovascular
risk is elevated in both conditions and several studies have evaluated and compared the
risk for RA and DM. Second, the risk of inflammation plays a role in both conditions. In
RA, the immune system attacks joints creating ongoing inflammation. Diseases with a
relevant component of inflamation, like RA, increase markers of inflammation, like CRP,
that have shown previous association with DM. On the other hand, inflammation is
associated with insulin resistance; which impairs the body’s ability to respond to insulin
adequately, increasing the risk of developing T2DM. In addition, some treatment for RA
like NSAIDs and corticosteroids could increase blood glucose levels increasing the risk
of DM; while other treatments like TNF inhibitors and hydroxychloroquine were related
with a decreased risk of DM in patients with RA
A review of the existing literature was conducted to find available research related
to the potential association between T2DM and RA. Different studies designed to
investigate other areas had noted a potential association between DM and RA but only
few addressed the direct relationship between both conditions. Available research
specific to this association is limited, and results are not clear or consistent to answer the
question.
Cardiovascular Risk for RA and DM
The majority of the research available for DM and RA is related to the
relationships between both conditions, independently, with the risk of CVD. Based on
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literature relevant to RA, it has been demonstrated that RA is characterized by elevated
cardiovascular morbidity and mortality; however, the reason is not clear (Kitas & Erb,
2003). Potential reasons are risk factors associated with CVD as well as RA including
obesity, insulin resistance, hypertension, atherosclerosis, and dyslipidemia
(Stamatelopoulus et al., 2009a). Other research indicates the increase of cardiovascular
morbidity and mortality with RA could be related to systemic inflammation found in this
condition (Sattar et al., 2003).
On the other hand, looking at diabetes, CVD has been identified as the major
complication of diabetes and is the primary cause of early death among people with this
condition. About 65% of people with diabetes die from heart disease and stroke. Adults
with diabetes are 2 to 4 times more likely to have heart disease or suffer a stroke than
people without diabetes (NIH, 2007).
It is recognized that both conditions, DM and RA, are connected with an
increased risk of CVD. Several investigations have been performed to compare the
potential risk of different elements of CVD in both RA and DM. The following section
summarizes the information available in this area.
Karanasos et al. (2011) investigated if RA is associated with increased
cardiovascular morbidity compared with DM. As a result, the authors found that RA
patients in the absence of obstructive coronary artery disease (CAD) may display
myocardial ischemia at similar levels to DM and higher than matched control subjects.
Another publication from Karanasos et al (2012) shows a prospective evaluation of the
possible presence of myocardial ischemia, by dobutamine stress-contrast
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echocardiography in asymptomatic patients and comparison to patients with DM and a
control group. Results showed that symptomatic patients with RA exhibited high
myocardial ischemic burden which was comparable to patients with DM. It was found
that myocardial ischemia was common in patients with no obstructive CAD. Positive
stress result was found in 67% of RA patients, 78% of DM patients, and 31% of controls
(p<0.05 for RA vs. control, p<0.01 for DM vs. control, p = NS for RA vs. DM).
Similarly, Zampeli et al. (2012) evaluated the presence of silent myocardial
ischemia in patients with RA versus patients with DM. They found significant CAD in
patients with positive stress ECHO results was more common in DM (50%) and controls
(73%) than in RA patients (25%). The conclusions in this case could imply the presence
of microvascular rather than coronary abnormalities as a result of elevated myocardial
ischemic burden by dobutamine stress-contrast echocardiography in the absence of
obstructive CAD exhibit by asymptomatic patients with RA.
Lindhardsen et al. (2010) completed a study to compare the incidence of
myocardial infarction (MI) in patients with RA or DM using prescription claims,
hospitalizations, and outpatient visits through individual-level-linkage nationwide
administrative registers. The overall incidence rate ratio of a MI event after developing
RA was increased to 1.61 (95% CI 1.42 to 1.83), which was comparable to the risk of MI
after developing diabetes of 1.70 (95% CI 1.59 to 1.83). Aligned with previous
investigations, the study found that the risk of MI is especially high among younger
patients with RA. Similar to what has been found in DM, this study concluded that RA is
an independent risk factor for MI.
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A study was performed by Yazdanyar el al. (2012) to determine whether the risks
of perioperative death and CV events among patients with RA differed from those among
unaffected controls and patients with DM. The authors concluded that RA was not
associated with adverse perioperative CV risk or mortality risk. In this research, the cases
were classified by severity of risk (low-risk, intermediate-risk, or high-risk noncardiac
procedure). Results showed 2.34% of patients with low risk had a composite CV event,
and death occurred in the 2.34% of patients. For intermediate and high risk, the numbers
were 0.51%, and 2.12% for composite CV event and 0.50%, and 2.59%, for death,
respectively. Death was less likely in RA patients than in DM patients (0.30% versus
0.65%; p< 0.001) for patients undergoing an intermediate-risk procedure, but the
difference in mortality rates among those undergoing low-risk versus those with high-risk
procedures was not significant. Patients with RA were less likely to have a CV event than
patients with DM for procedures of low risk (3.38% versus 5.30%; p < 0.001) and
intermediate risk (0.34% versus 1.07%; p < 0.001). After evaluation using adjusted
models, RA was not independently associated with an increased risk of perioperative
death or a CV event.
A 3-year prospective study performed by Peters et al. (2009) indicates that the
risk of CVD in RA was significantly elevated compared with the general population and
comparable with the extent of the risk in T2DM. For this study, the incidence of CVD in
patients with RA was 9% in comparison to 4.3% in the general population. The hazard
ratio (HR) for patients without diabetes and with RA (2.16) was comparable with those
with T2DM (2.40).
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In a cross-sectional study evaluating the risk of CVD between DM and RA, it was
concluded that the prevalence of CVD was elevated comparable with what is found in
T2DM. Prevalence in the population without diabetes was 5% versus 12.4% found in the
population with diabetes and 12.9% in the population with RA (Van Halm et al., 2009).
Stamatelopoulos et al. (2009a) concludes that atherosclerosis (vascular condition
in which an artery wall thickens as a result of the accumulation of fatty materials such as
cholesterol) is equal on the severity and frequency in patients with DM or RA. The study
results reinforced the fact that CVD risk factors need to be addressed for patients with
DM but also for patients with RA.
Yazdanyar et al. (2010) performed a cross-sectional analysis of the National
Inpatient Sample of the HealthCare Utilization Projects using data from years 1998 to
2002 to compare the risk of perioperative cardiovascular outcomes in a hospital setting
among patients with RA, DM, both conditions, and neither condition. The study results
indicated that RA was not an independent predictor of perioperative cardiovascular
events including acute MI, acute stroke, non-ST elevation MI (ST segment elevation
indicates that a relatively large amount of heart muscle damage is occurring, because the
coronary artery is totally blocked), and/or congestive heart failure with pulmonary
edema. Conversely DM was associated with increased odds of cardiovascular outcomes
across all surgical risk levels.
As indicated in the previous summary, there is substantial evidence for increased
cardiovascular risk in RA comparable to what is found in DM. Some researchers have
questioned if patients with DM and concomitant RA could have doubled cardiovascular
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risk, but no data was found in this area. Do patients with T2DM have increased risk of
RA in comparison with patients without T2DM? Is the risk of CVD in RA similar to the
risk of CVD in T2DM because both conditions are related and because the risk factors or
characteristics are similar? Is the risk of CVD a bigger concern for patients having both
conditions?
Systemic Inflammation
Another area of interest in the relationship between RA and DM is the potential
systemic inflammation that is present in RA including markers and how it could
potentially link with insulin resistance. If inflammation can promote insulin resistance,
the prevalence of the metabolic syndrome may be increased in patients with RA, which at
the same time is indicative of increased risk for CVD. The potential role of insulin
resistance as a cardiovascular risk factor in patients with inflammatory arthritis has been
examined. Schmidt et al. (1999) found that markers of inflammation are associated with
the development of diabetes in mid age adults reflecting the pathogenesis of T2DM. The
authors of this study indicated that insulin resistance may help in the development of
inflammation instead of being a consequence of high concentrations of inflammatory
mediators (Schmidt et al., 1999).
MacLennan (2007) reported that arthritis and diabetes are characterized by high
levels of CRP and interleukin-6 (II-6), markers of inflammation; however no association
between both conditions was found.
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Drug Therapies Affecting RA and DM
Treatment for both conditions has been investigated as potential positive and
negative factors in this association. For RA, NSAIDs and corticosteroids are known for
their negative effect in blood glucose levels which increase the risk of DM; while other
drugs like TNF inhibitors and hydroxychloroquine were related with a positive risk
decrease of DM in patients with RA (Wasko et al., 2011; Antohe et al., 2010; Antohe et
al., 2012; Bili et al., 2011; Solomon et al., 2010b; Solomon et al., 2011; Sasaki et al.,
2010; Yokota & Igaki, 2012).
Behaviors Affecting DM and RA
On the behavioral side, it is important to mention elements that could affect both
conditions: physical activity, or the opposite, inactivity. Based on information from the
ADA and the American College of Sports Medicine, physical activity could reduce blood
glucose and risk factors for complications (e.g., obesity and hypertension) in persons with
diabetes and could improve CVD outcomes. Considering RA, this is a very important
factor because physical activity can decrease pain and improve functionality, mobility,
mood, and quality of life for most adults with many types of arthritis including RA.
Inactivity could negatively affect both conditions, RA and T2DM. Based on information
from the BRFSS from 2005 to 2007, the prevalence of physical inactivity is higher for
those patients with DM and RA (29.8%) in comparison with those who had only one or
none of these two conditions (diabetes alone -21.0%). This association was independent
of age, sex, or BMI (CDC, 2008).
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Key Variables Literature Review and Methodology Concepts
Few studies were found that directly evaluate the question related to the
association between T2DM and RA. First, an evaluation of the cross-sectional association
between prevalent RA and DM among institutionalized U.S. civilians aged 60 years or
older was completed by Simard and Mittleman in 2007. The authors performed a similar
study design (cross-sectional investigation) to what was performed in this investigation
using NHANES; however, they focused their study specifically on the elderly population
and data used are dated (1988-1994). This study was not able to bring positive or
negative evidence of a strong cross-sectional association between prevalent RA and DM.
Only 144 participants were identified with RA, and there were 24 who also had prevalent
DM (17%) compared with 16% (n = 815) of the 5152 participants without RA (p = 0.46).
Using a logistic regression model controlling for age and sex, the odds ratio for the
RA-DM association was 1.3 (95% CI 0.68 to 2.3). Results were not different after
multivariate adjustment also controlling for race, smoking, and education. The authors
indicated that the sample found was not enough for this investigation. The current study
addresses the potential limitations of this study to achieve successful results.
Tentolouris et al. (2008) completed a prospective study to determine the presence
of concomitant RA in consecutive DM patients who were regularly followed up for at
least 10 years in an outpatient clinic setting. The results showed a prevalence of RA of
0.38% in all DM patients (3 patients with T1DM and 2 patients with T2DM) which was
not significantly lower than that in the control group [0.65% (17 patients); p = 0.36]. This
study was not able to make any valid conclusions due to the relatively small size of the
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group. The authors indicated that if the RA prevalence persists at the 0.25% level using a
larger DM data set, the difference from the general population would easily reach
significance (i.e. Yate’s χ 2 -test 4.44) when 1500 patients with T2DM are studied.
Solomon et al. (2010a) completed a retrospective study to examine the risk of DM
among patients with RA, psoriatic arthritis or psoriasis (PsA/PsO), compared with
nonrheumatic controls. In this case, the groups were assembled using linked healthcare
utilization data from British Columbia, Canada. The incident rates (IRs) for DM among
patients with RA was 8.6 per 1000 person-years (95% CI 8.5 to 8.7) and for
nonrheumatic controls was 5.8 (95% CI 5.8 to 5.8). The adjusted hazard ratio (HR) for
RA compared with nonrheumatic controls was 1.5 (95% CI 1.4 to 1.5). As per the study
results, it is suggested that RA may be related to a higher risk of DM.
Dubreuil et al. (2012) evaluated the risk of incident DM in PsA and RA, in the
UK general population (1986 and 2010), with adjustment for BMI and lifestyle factors.
Age and sex matched HR for DM was 1.12 (95% CI 1.01 to1.25) in RA relative to the
comparison groups. After adjustment for BMI, smoking, and alcohol use, this HR was
attenuated substantially (1.00). With further adjustment for glucocorticoid use and
comorbidity index, the HR was 0.94 (95% CI 0.84 to 1.06) in RA. The results of this
study indicated that the risk of DM among patients with RA is significantly elevated only
due to increased BMI and smoking. These results suggest that diabetes risk should not be
attributed only to the presence of inflammatory disease.
This study concluded that risk of DM between patients with RA is significantly
higher; however the results indicated that the reason for this is mostly due to increase in
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factors such as BMI and smoking and not due to the factor of inflammation. Finally,
Bartels et al. (2012) examined how the presence of RA affected HbA1c and lipid
measurements in older adults (aged 65 or older) with DM using Medicare data. The main
reason for this investigation was not the relation between RA and DM; however, it was
included in the review to document important data related to the topic. Similar to Simard
and Mittleman, the authors in this investigation concentrated their efforts on a specific
population. In this case, only 2% of the DM population had comorbid RA (n = 5572).
DM patients with comorbid RA were more likely than those without RA to have baseline
CVD (such as 17% more congestive heart failure), diabetes-related complications
including kidney disease (19% higher), lower extremity ulcers (77% higher), and
peripheral vascular disease (32% higher). In adjusted models, DM patients with RA were
less likely to receive recommended HbA1c testing (OR 0.84, 95% CI 0.80 to 0.89) than
those without RA, but were slightly more likely to receive lipid testing (OR 1.08, 95% CI
1.01 to 1.16). Interestingly, for older adults with DM, the presence of comorbid RA
predicted lower rates of HbA1c testing but slightly improved lipid testing.
As previously discussed in this literature review, other investigations have used
the quantitative cross-sectional methodology to clarify this type of question. This study
aims to evaluate the potential association between T2DM and RA including
determination of crude and adjusted prevalence for the population. Cross-sectional and
quantitative investigation is the appropriate methodology for this type of inquiry because
this methodology can be used to describe the population, such as prevalence of an illness
which is the main objective for this investigation. This is an evaluation of the population
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at one point in time to capture and describe patients’ characteristics, outcomes, and risk
factors. Based on the inconsistency found in the literature so far on this topic, the design
of the current study is adequate to determine potential association between these two
diseases. The quantitative methodology of the current study is an appropriate way to test
theories as an alternative of qualitative research, which is more relevant for new concepts
with minimum research available. As previously mentioned, Simard and Mittleman
(2007) used this methodology to investigate this relationship; however their study had
some limitations that will be considered in this study. Several investigations have
successfully used a cross-sectional methodology to determine prevalence of other
conditions using representative U.S. data from NHANES. For example, this methodology
and data source have been used to determine the prevalence of obesity in the United
States (Ogden et al., 2012). Findings of this research include: more than one-third of
adults and almost 17% of youth were obese in 2009–2010; there was no change in the
prevalence of obesity among adults or children from 2007–2008 to 2009–2010; obesity
prevalence did not differ between men and women; and adults aged 60 and older were
more likely to be obese than younger adults. Another related investigation that
successfully utilized this methodology was performed by Coresh et al. (2003) to
determine the prevalence of Chronic Kidney Disease (CKD) in the U.S. population. The
prevalence of CKD in the U.S. adult population was 11% (19.2 million), and prevalence
was also determined by disease stage (Coresh et al., 2003).
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Summary
Given the potential association with CVD, insulin resistance, high levels of
inflammatory markers, and other behaviors such as inactivity, the question arises whether
patients with DM have an increased risk of RA or have RA as comorbidity. This review
of literature served as the basis for this potential association; however, there are no
studies to date that have directly answered the question of the association between DM
and RA in the general U.S. population. If these two important conditions are related,
health care providers and patients should start managing both diseases on an
interdisciplinary manner and combining efforts for the benefit of the patient.
Chapter 3 will define the research methods for this study including the definition
of the population and variables to be evaluated. This next chapter will also describe the
data to be used including procedures for recruitment, participation, and data collection.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine if any association exists between
T2DM and RA for noninstitutionalized U.S. adults between 1999 and 2012. This study
also describes potential characteristics that may be important in understanding this
comorbidity, including the potential high prevalence of CVD. Chapter 3 explains the
methodology that was utilized to perform this investigation and answer the research
questions.
This chapter explains the study design and includes a description of the study
population, criteria for sample selection, definition of variables, and original data
collection methodology. General information about the current data set and data analysis
is described. The ethical protection of participants—including IRB review, privacy and
patients’ rights—are also discussed.
Research Design and Rationale
This quantitative, cross-sectional investigation explored whether patients with
T2DM (independent variable) have increased prevalence of RA (dependent variable)—
compared with patients without T2DM—using a U.S. nationally representative sample
and adjusting for the following potential confounding factors, as evidenced in the
literature review: gender, age, race/ethnicity, education level, and smoking status
(Simard & Mittleman, 2007).
I sought to answer the following research questions by testing their associated
hypotheses:
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1. Do patients with T2DM have statistically significant increased prevalence of
RA in comparison with patients without T2DM?
H01:
- Patients with T2DM do not have a statistically significant increased
prevalence of RA compared to patients without T2DM, after adjustment for
potential confounders.
HA1: with T2DM do have a statistically significant increased prevalence of
having RA compared to patients without T2DM, after adjustment for potential
confounders.
2. What demographic, lifestyle, or clinical characteristics are significantly
different for those patients with RA and T2DM in comparison with patients
with RA but no presence of T2DM?
Is there a difference in prevalence of RA based on the specific demographic,
lifestyle, or clinical characteristics in patients with and without T2DM?
H02a:
- Patients with T2DM do not have a statistically significant different
prevalence of RA compared to patients without T2DM based on specific
demographic, lifestyle, or clinical characteristics.
HA2a:
- Patients with T2DM do have a statistically significant different prevalence of
RA compared to patients without T2DM based on specific demographic,
lifestyle, or clinical characteristics.
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Characteristics evaluated on this inquiry are demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability,
smoking status, and work functioning), and clinical (blood pressure levels,
BMI, lipid levels [HDL/LDL, TC], CRP, use of antirheumatic medications,
and presence of CVD).
3. What demographic, lifestyle, or clinical characteristics are significantly
different for those patients with RA and T2DM in comparison with patients
with T2DM but no presence of RA?
Is there a difference in prevalence of T2DM based on the specific
demographic, lifestyle, or clinical characteristics in patients with and without
RA?
H03a:
- Patients with RA do not have a statistically significant different prevalence
of T2DM compared to patients without RA based on specific demographic,
lifestyle, or clinical characteristics.
HA3a:
- Patients with RA do have a statistically significant different prevalence of
T2DM compared to patients without RA based on specific demographic,
lifestyle, or clinical characteristics.
Characteristics evaluated on this inquiry are demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability,
smoking status, and work functioning); and clinical (blood pressure levels,
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BMI, lipid levels [HDL/LDL, TC], presence of CVD, plasma glucose, and
HbA1c).
4. Do patients with T2DM and concomitant RA have a statistically significant
higher prevalence of CVD in comparison with patients with T2DM and no
presence of RA and patients with RA and no presence of T2DM?
H04a:
- Patients with T2DM and concomitant RA do not have a statistically significant
increased prevalence of CVD compared to patients with T2DM and no presence
of RA and patients with RA and no presence of T2DM, after adjustment for
potential confounders.
HA4a:
- Patients with T2DM and concomitant RA do have a statistically significant
increased prevalence of CVD compared to patients with T2DM and no presence
of RA and patients with RA and no presence of T2DM, after adjustment for
potential confounders.
The current study proposed a secondary analysis of cross-sectional data from a
large nationally representative data set, the continuous NHANES. Per definition, crosssectional data is information collected at one time point or over a short period. This type
of study provides information that is typically used to estimate the prevalence of the
outcome of interest for a given population, and it is very useful to support public health
planning and interventions. Information on individual characteristics, including exposure
to risk factors, in conjunction with information about the outcome, may also be collected

64
in this type of study. Cross-sectional studies provide a snapshot of the outcome and the
characteristics associated with it at a specific point in time, which is exactly the intended
purpose of this investigation.
At this point, the researcher wants to describe a U.S. population with respect to an
outcome and a set of risk factors. As previously mentioned in Chapters 1 and 2, studies
performed so far are not clear whether there is an increased prevalence of DM in patients
with RA or vice versa. The few studies that have been conducted to evaluate the potential
association between DM and RA are not consistent. One study performed by Simard and
Mittleman concluded no association between RA and DM. This study was in some areas
limited because it did not include the general population (only people aged 60 years and
older), and only data from 1988 to 1994 was evaluated (Simard & Mittleman, 2007). A
study completed by Tentolouris et al. (2008) evaluated the presence of concomitant RA
in patients with DM who were followed for at least 10 years. This study was not able to
make any conclusions due to the relatively small cohort. Another study completed by
Solomon et al. (2010a) examined the risk of DM in patients with RA between other
conditions. As a result, RA appeared to be associated with an increased risk of DM;
however this increased risk decreased with age. By author recommendation, this study
needs replication. Dubreuil et al. (2012) evaluated the risk of incident DM in RA and
found that the risk of DM among patients with RA is significantly elevated only due to
increased BMI and smoking. Based on the inconsistency found in the literature to date on
this topic, the design of this study may be able to clarify potential noncausal association
between these two conditions. This quantitative methodology is an appropriate way to
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test theories as an alternative of qualitative research, which is more relevant for new
concepts with minimum research available.
As mentioned in Chapter 2, Simard and Mittleman used this methodology
previously; however, the data was not sufficient to make any conclusions for their
research. In this present study, the author is evaluating a larger sample including
additional and more recent years to increase the power of the study, which was
previously an issue and, thus, answer the question appropriately at this phase. In addition,
the first three questions will also be analyzed considering the variable “age of diagnosis,”
which will exclude from the sample those diagnosed with RA before DM or vice versa as
applicable. Prospective and longitudinal design could be a next step to confirm the results
of this study; however time and budgets considerations need to be evaluated for this type
of study design. The next possible approach (prospective and longitudinal research) also
gives the opportunity to obtain and evaluate prospective data specific to particular
elements that cannot be captured in this design (e.g., RA symptoms such as joint pain and
potential association to glucose control over time).
Time and resources are not constraints in this current investigation. Using existing
cross-sectional data, particularly from NHANES, has advantages: (a) inexpensive public
database; (b) takes less time to conduct and no patients recruitment is requirement; (c)
can estimate the prevalence of outcome of interest because the sample is from a
nationally representative source; and (d) a variety of outcomes and risk factors can be
assessed.
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The crude prevalence of RA will be calculated for patients with T2DM and with
no presence of T2DM. A logistic regression analysis will be performed taking surveys
weight into consideration to generate estimates of the U.S. population. Covariates
identified in the literature as potential confounders (gender, age, race/ethnicity, education
level, and smoking status) will be considered to mitigate confounding bias during the
analysis. The adjusted ORs for the association between T2DM and RA will be
determined.
Using a group of patients with presence of RA among patients with and without
T2DM, this study will identify and describe potential characteristics that could
differentially affect the prevalence of RA within the groups. Characteristics to be
evaluated on this inquiry are demographic (age, gender, race/ethnicity, education level,
and poverty level); lifestyle (disability, smoking status, and work functioning) and
clinical (blood pressure levels, BMI, lipid levels [HDL/LDL, TC], CRP, use of
antirheumatic medications, and presence of CVD).
Using a second group of patients with the presence of T2DM among patients
with and without RA, the study will also identify and describe potential characteristics
that could differentially affect the prevalence of T2DM. Characteristics to be evaluated
on this inquiry are demographic (age, gender, race/ethnicity, education level, and poverty
level); lifestyle (disability, smoking status, and work functioning); and clinical (blood
pressure levels, BMI, lipid levels [HDL/LDL, TC], presence of CVD, plasma glucose,
and HbA1c).
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Using the addition of a third group of patients with T2DM and concomitant RA,
the study will evaluate and compare the prevalence of CVD for three groups (DM plus
concomitant RA, RA with no T2DM, and T2DM with no RA) in comparison with
individuals without any of these two conditions (no RA with no T2DM).
Additional analysis using logistic regression will be performed to adjust for all
other potential covariates in the last three inquires. This technique attempts to reduce the
bias due to confounding variables.
Considering the fact that no specific study concludes that there is a real
association between DM and RA, this study will help to identify the possible association
between DM and RA and any important elements to be considered for this association.
The current study employs a quantitative, cross-sectional design using data from the large
nationally representative data set, NHANES. Data analysis will be performed using SAS.
Methodology
Study Population
This study comprises adult (18 years and older) including patients with T2DM
and concomitant RA, patients with T2DM and no presence of RA, and patients with RA
and no presence of T2DM using NHANES data sets from 1999 to 2012.
Data Source and Sampling Procedure
The data source for this investigation is the continuous NHANES, which is one of
the most important programs driven by the National Center for Health and Statistics
(NCHS) as part of the CDC in the United States. The purpose of this effort is to maintain
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continuous assessment of the health and nutritional aspects of adults and children in the
United States (CDC, 2012b).
The NHANES program began in the early 1960s and has been conducted as a
series of surveys focusing on different population groups or health topics. Since 1999, the
survey became a continuous program aiming to cover a variety of measurements to
describe and evaluate health and nutrition of the U.S. population. This data set offers the
benefit of having interviews as well as physical examinations for better evaluation of
health. Data collection includes: (a) the interview, which consists of demographic,
socioeconomic, dietary, and health-related questions and (b) the examination component,
which consists of medical, dental, and physiological measurements and laboratory tests
(CDC, 2012c).
Benefits of conducting a secondary data analysis using NHANES are: (a) data is
generalizable to a wider population, (b) low cost and time (because data are already
collected), and (c) better statistical validity. Information gathered from this database has
been used to influence policy and improve public health (CDC, 2012b).
The procedure NHANES uses to select participant is complex and multistage, and
uses a probability sampling design. This process allows having a sample that is
representative of the civilian, noninstitutionalized U.S. population. The sample does not
include persons residing in nursing homes, members of the armed forces, institutionalized
persons, or U.S. nationals living abroad.
As published by the CDC, the process of sampling used in NHANES consists of 4
stages that are described below (CDC, 2012b):
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•

Stage 1: Primary sampling units (PSUs) are selected. These are mostly
single counties or, in a few cases, groups of contiguous counties with
probability proportional to a measure of size (PPS).

•

Stage 2: The PSUs are divided into segments (generally city blocks or
their equivalent). As with each PSU, sample segments are selected with
PPS.

•

Stage 3: Households within each segment are listed, and a sample is
randomly drawn. In geographic areas where the proportion of age, ethnic,
or income groups selected for oversampling is high, the probability of
selection for those groups is greater than in other areas.

•

Stage 4: Individuals are chosen to participate in NHANES from a list of
all persons residing in selected households. Individuals are drawn at
random within designated age-sex-race/ethnicity screening subdomains.
On average, 1.6 persons are selected per household.

The sampling design used by NHANES includes sample weights allowing for
calculation of population-based estimates of variables (CDC, 2012b). This strategy
decreases the opportunity of having selection bias and increases the reliability of the data
analysis. This is due to the fact that NHANES oversamples limited populations such as
elderly (60 years and older), African Americans, and Hispanics. Notably, beginning in
2007, a new sampling methodology was implemented; however this does not affect the
analysis for the current study. As part of this change, NHANES oversampled different
populations including:
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•

All Hispanics, not just Mexican Americans

•

For each of the race/ethnicity domains, the 12-15 and 16-19 year age
domains were combined and the 40-59 year age domains were split into
10-year age domains 40-49 and 50-59.

It is important to note that women were no longer oversampled.
The population evaluated in this survey consists of approximately 5000 persons
from all ages in the United States every year. Considering the size of the U.S. population,
the opportunity of being a participant of this program in more than one “2 year cycle” is
minimal or almost null (CDC, 2012b). After 1999, NHANES includes a continuous
design that brings flexibility to combine data or variables over several cycles. This gives
the investigators the opportunity to evaluate rare conditions or to target small
populations. In this way, researchers have the opportunity to study larger population size
and also to include more variables without losing statistical power during data analysis
due to these factors. Table 1 includes the description of this concept as it will be used in
the current study:
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Table 1.
Details of Continuous Design of the Data per Year
Survey cycle

Data
processing
years
2001-2002

Data
release
years
2002

Analysis years

NHANES 1999-2000

Data
collection
years
1999-2000

NHANES 2001-2002

2001-2002

2003

2004

2004+

NHANES 2003-2004

2003-2004

2005

2006

2006+

NHANES 2005-2006

2005-2006

2007

2008

2008+

NHANES 2007-2008

2007-2008

2009

2010

2010+

NHANES 2009-2010

2009-2010

2011

2012

2012+

NHANES 2011-2012

2011-2012

2013

2013

2013+

2002+

Selection Criteria and Power Analysis
NHANES has standardized procedures to access population groups that are
challenging to recruit such as the elderly. RA and T2DM will be identified using specific
criteria for the target population of adults 20 years old and older. The age of 20 year and
older is selected because only participants over 20 years of age are approached to respond
to the arthritis questions. For RA, it is considered all patients that have self reported RA
with a positive response to arthritis and RA in the following questions: Doctor ever said
you had arthritis? If so, Which type of arthritis? rheumatoid arthritis?
In case of diabetes, type of diabetes is not defined in continuous NHANES so a
previously used algoritm is use to define T2DM population. Based on this algorithm, the
first step is to identify patients 20 years old and older who self-report diabetes. As
previously mentioned, the age of 20 year and older is selected because only participants
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over 20 years of age are approached to respond to the arthritis questions. A participant is
considered to have diabetes if he or she answered Yes to the question ther than during
pregnancy, have you ever been told by a doctor or healthcare professional that you have
diabetes or sugar diabetes? This method has been used in previous publications
(Berkowitz, 2013; Heliovaara et al., 1993; Midthjell et al., 1992; Kehoe et al., 1994). To
minimize inclusion of patients with T1DM, patients who were diagnosed before the age
of 30 and initiated insulin within one year of diagnosis are excluded. This approach is in
accordance with previous evaluations ofNHANES data (Koopman et al., 2005; Seligman,
et al., 2007). Sensitivity of this measure has been reported to be more than 95% in
previous NHANES analyses (Seligman et al., 2007), and specificity has been reported to
be as high, at 97% (Kehoe et al., 1994). Participants with biochemical but not selfreported diabetes are not included because age at diagnosis could not be determined in
these cases. Women reporting diagnosis of diabetes during pregnancy are excluded.
NHANES has the benefit of allowing researchers to use single or multilayer data
sets. This is possible because surveys were conducted as a continuous annual survey with
periodic releases every two years. To achieve a better sample size and optimize validity
for this study, data from 1999 to 2012 is evaluated. It is generally accepted to use alpha
of 0.05 and and power estimates of 0.80 to determine an appropriate sample size via
power analysis. For the primary analysis of the association between T2DM and RA, the
study has a power of 0.89 to detect an absolute risk diference of 1.5% (OR: 1.32) with
two tailed test and alpha of 0.05. This calculation was performed using N-Query Advisor
[PTT0U-1,nqa] (Machin & Campbell, 1987)

73
The approximate size of the total population of interest is 30,878 including
approximately 329 participants with T2DM and concomitant RA; 2,366 participants with
T2DM and no presence of RA; 1,183 participants with RA and no presence of T2DM;
and 23,073 with neither condition.
The following section defines and explains the elements considered in the present
study including definitions of primary variables and covariates. Definition of the problem
and research questions were defined in previous sections of this chapter.
Study Variables
DM: Patients with T2DM were identified based on the self-reporting of this
condition through the following question: Other than during pregnancy, have you ever
been told by a doctor or healthcare professional that you have diabetes or sugar
diabetes? To minimize inclusion of patients with T1DM, patients who were diagnosed
before the age of 30 and initiated insulin within one year of diagnosis are excluded.
Participants with biochemical but not self-reported diabetes are not included because age
at diagnosis could not be determined in these cases. Women reporting diagnosis of
diabetes during pregnancy are excluded
RA: Patients with RA were identified based on the self-reporting of this condition
through the following questions: Has a doctor or other health professional ever told
{you/SP} that {you/s/he} . . .had arthritis? If so, Which type of arthritis was it?
Rheumatoid arthritis?
Age: Captured as the age when participant completed the survey. For the purposes
of the study this variable is continuous.
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Gender: Captured as a dichotomous categorical variable. Categories: male (0) and
female (1).
Race/ethnicity: Captured as a categorical variable using the following categories:
Hispanic, Non-Hispanic White, Non-Hispanic Black, and Other (including multiracial
persons).
Education level: Captured as a continuous variable using the following
categories: at least ninth grade, 9- 11th grade, high school graduate, some college, and
college graduate.
Poverty level: Measured by the NHANES as poverty income ratio (PIR).
Continuous and binary categorical variable with PIR values below 1.00 considered as
being below the official poverty threshold = poor, whereas PIR values of 1.00 or greater
indicating income values above the poverty level = not poor as determined by the U.S.
Bureau of the Census and updated annually for inflation with the Consumer Price Index
(USCB, 2011).
Smoking: Categorical variable with the following classifications: never, past
smoker (>6 months not smoking), and current smoker (≤6 months since last smoked).
Disability: Categorical variable with the following classification: Yes = evidence
of mental or physical disability and No = No evidence of disability. Evidence of disability
is operationally defined using Items 2–4 from the four-item CDC Measuring Healthy
Days questionnaire. The Healthy Days scale was developed by a working unit from the
CDC as a way to measure Health Related Quality of Life (HRQoL) in population
surveys. The MOS SF-36 and the Quality of Well-Being scale were considered too long
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for use in public health surveillance for phone interviews, so the three-item parsimonious
Healthy Days approach was adopted. The three questions are listed below. Item 1 asks
only about general health and therefore does not provide sufficiently specific data to
measure disability.
•

(2) Thinking about your physical health, which includes physical illness
and injury, for how many days during the past 30 days was your physical
health not good?

•

(3) Now thinking about your mental health, which includes stress,
depression, and problems with emotions, for how many days during the
past 30 days was your mental health not good?

•

(4) During the past 30 days, for about how many days did poor physical or
mental health keep you from doing your usual activities, such as self-care,
work, school or recreation?

Items 2, 3 and 4 each report a range of 0 to30 days when health was not good or
activity was limited. Items 2 and 3 are frequently tallied together and a score of any days
when physical or mental health was not good up to a total of 30 days is calculated,
because activity limitations can be from physical or mental health. Mean number of
unhealthy days for persons in the general public were reported as ranging from 5.1 at age
40 to 6.7 days at age 75 or greater. No disability is recorded for 0 to 13 days, but 14 to 30
days is recorded as disability for questions two through four. The same operational
definition of disability for Physical, Mental and Activity will be used in this study: 0 to
13 days = no disability and 14 to 30 days = disability. Disability for several chronic
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diseases is monitored at the state and territory level by the BRFSS using the CDC
HRQOL-4 in population surveys. Reliability and validity have been well established
during the extensive use of this scale in state and national health monitoring through the
BRFSS. The same definition was used independently for mental and physical disability.
Work functioning: Categorical variable with the following classification: Yes =
inability to work and No = No evidence of inability to work using the following question:
Does a physical, mental or emotional problem now keep you from working at a job or
business?
Blood pressure levels: BP as two continuous variables namely systolic BP and
diastolic BP.
Hypertension: Captured as a categorical variable (Yes or No).
BMI: Height and weight measurements were obtained using standardized
techniques and equipment. BMI will be calculated using the following formula: BMI =
weight (kg)/height2 (m2).
Obesity: This variable was used as a categorical variable using the following
classification: BMI of < 25 kg/m2 = normal, 25 to 29 kg/m2 = overweight, and
> 30 kg/m2 = obese
Lipid levels (HDL, LDL, and TC): For the current study, HDL, LDL, and TC
were assessed as continuous variables considering recommendations from the AHA
(AHA, 2014). Considering HDL cholesterol, higher levels are better. Low HDL
cholesterol puts you at higher risk for heart disease. People with high blood triglycerides
usually also have lower HDL cholesterol. In case of the LDL or better known as bad
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cholesterol; a low LDL cholesterol level is considered good for your heart health.
However, your LDL number should no longer be the main factor in guiding treatment to
prevent heart attack and stroke, according to new guidelines from the American Heart
Association. A total cholesterol score is calculated using the following equation:
HDL + LDL + 20 percent of your triglyceride (most common type of fat in the body)
level. A total cholesterol score of less than 180 mg/dL is considered optimal.
CRP: Continuous variable. CRP level was measured directly from serum using
latex enhanced nephelometry.
Use of antirheumatic medications: Categorical variable with the following
classification:
•

Antirheumatics (including biologic response modifiers): Yes = number of
patients with any evidence of use of antirheumatics including biologics;
No = no evidence

•

Glucocorticoid: Yes = number of patients with any evidence of use of
Glucocorticoids; No = no evidence

•

Analgesics: Yes = number of patients with any evidence of use of
analgesics; No = no evidence

Plasma glucose: Continuous variable. Measures are fasting.
HbA1c: Continuous variable.
CVD: Categorical variable with the following classification: Yes = evidence of
any congestive heart failure, coronary heart disease, angina, angina pectoris, and heart
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attack; No = no evidence of congestive heart failure, coronary heart disease, angina,
angina pectoris, and heart attack.

NHANES

T2DM

T2DM/RA
Group 1

T2DM/RA (-)
Group 2

T2DM (-)

T2DM (-)/RA
Group 3

T2DM (-)/RA (-)
Group 4

Figure 5. Study groups diagram.
Data Analysis
All statistical analyses are “design-based” so the complex survey sampling design
is utilized in SAS procedures such as SURVEYFREQ, SURVEYMEANS, and
SURVEYLOGISTIC. For Objective 1, the analysis investigates the cross- sectional
association between T2DM and RA using a logistic regression with T2DM as the
independent variable and RA as the dependent variable. Adjusted OR of RA is
determined considering the following confounding: age, sex, race/ethnicity, education,
and smoking as previously determined by Simard and Mittleman (2007).
For Objective 2, Groups 1 and 3 from the study group diagram (Figure 5) are used
to identify patients with the presence of RA among patients with and without T2DM.
Logistic regression was performed using RA as the dependent variable and characteristics
of T2DM as the independent variable to determine univariate ORs. This analysis
describes potential characteristics that are statistically significantly different comparing
prevalence of RA within T2DM in comparison with prevalence of RA within participants
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with no presence of T2DM. Characteristics evaluated on this inquiry are demographic
(age, gender, race/ethnicity, education level, and poverty level); lifestyle (disability,
smoking status, and work functioning); and clinical (blood pressure levels, BMI, lipid
levels [HDL/LDL, TC], CRP, use of antirheumatic medications, and presence of CVD).
For the Objective 3, Groups 1 and 2 from the study group diagram (figure 5) are
used to identify patients with the presence of T2DM between patients with and without
RA.. Logistic regression was performed using T2DM as the dependent variable and
characteristics of RA as the independent variable to determine univariate ORs. This
analysis describes potential characteristics that are statistically significantly different
comparing prevalence of T2DM within participants with RA and prevalence of T2DM
within participants with no presence of RA. Characteristics evaluated on this inquiry are
demographic (age, gender, race/ethnicity, education level, and poverty level); lifestyle
(disability, smoking status, and work functioning); and clinical (blood pressure levels,
BMI, lipid levels [HDL/LDL, TC], presence of CVD, plasma glucose, and HbA1c).
This study uses chi square test to evaluate nominal, ordinal, and categorical
variables; this statistical test is commonly used to compare observed data with data
expected to be obtained according to a specific hypothesis. The chi-square test evaluates
the null hypothesis, which states that there is no significant difference between the
expected and observed result. For continuous variables with interval and ratio level data,
t-tests will be used. t-tests are tests for statistical significance that can be used in several
different types of statistical tests: (a) to test whether there are differences between two
groups for the same variable, based on the mean (average) value of that variable for each
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group; (b) to test whether a group's mean (average) value is greater or less than some
standard; (c) to test whether the same group has different mean (average) scores on
different variables.
Due to the amount of covariates to be considered in Objectives 3 and 4 and the
potential correlation between each, it is possible to confront an issue of multi-colliniarity
in the regression model. Collinearity is a data problem that has the consequences of
resulting in large standard errors. To minimize this problem, it was decided to obtain a
sample considering several years of the NHANES data set (1999-2012). More data can
produce more precise parameter estimates (with lower standard errors), as seen from the
formula in variance inflation factor for the variance of the estimate of a regression
coefficient in terms of the sample size and the degree of multicollinearity. Another
remedy for this phenomenon is redefining or eliminating variables. Then, variable
clustering could be used in this case, which may result in the dropping of nonimportant or
redundant variables to produce a model with better significant coefficients.
For Objective 4, the analysis describes and compares the prevalence rates of CVD
among patients with T2DM and comorbid RA, patients with T2DM and no presence of
RA, and patients with RA and no presence of T2DM. Logistic regression is used to assess
the interaction of RA and T2DM combined (independent variables) to determine if there
is association to CVD (dependent variable). This model is used with and without the
covariates listed previously.
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Threats to Validity
The current study proposes to use data from the continuous NHANES to evaluate
the association between T2DM and RA. The population studied in the continuous
NHANES represents a weighted, random sample of the civil, noninstitutionalized
population of the United States. It is important to document that the population sample
and limitations of the database will be applicable to U.S. population and may exclude
generalizations (external validity) to other countries especially with different health care
systems. NHANES data captures one point in time (cross-sectional design), which
provides almost no basis for drawing conclusions about causality; thus it is also important
to document that, as part of the limitations of this design, this study can only be used for
correlation. Additional prospective and longitudinal studies will be further needed if
correlation is found in order to demonstrate causality between variables.
Ethical Considerations
It was important to anticipate ethical issues that may be associated with the
present study and be proactive in protecting participants’ privacy and rights. This study
was conducted to clarify a question within the literature using NHANES data. Because
data were already collected, the study could not be affected by a personal influence. This
study constituted a secondary analysis of data and thus I had no access to personal data
and at the same time was not able to be in contact with participants. This fact eliminates
any potential opportunity of coercion.
All NHANES plans, procedures, and progress were reviewed and approved by the
IRB for the NCHS on a periodic basis.
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Before any procedure was completed or data were collected, the participant read
and voluntary signed an appropriate informed consent (previously reviewed and approved
by the IRB). In addition to the process followed by NHANES to protect participants’
privacy and rights, the IRB at Walden University reviewed and approved the current
investigation. The IRB approval number was 02-21-14-0123975.
Summary
Chapter 3 provided the methodology proposed to perform this quantitative, crosssectional investigation. The primary objective of this investigation is to identify if there is
any association between T2DM and RA for noninstitutionalized U.S. adults between
1999 and 2012 using a nationally representative sample from the NHANES. The current
study is intended to determine if patients with T2DM have increased prevalence of RA.
At the same time, the current study helps clarify which characteristics could differentially
affect the relationship between both groups and evaluate the potential increased
prevalence for CVD when this comorbidity exists. The results of the current study may
provide patients and care providers with a better understanding of the needs to manage
both conditions. Data analysis is performed using SAS software.
Results and findings from the study are presented in Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this study was to clarify if any association exists between T2DM
and RA for noninstitutionalized U.S. adults between 1999 and 2012. A quantitative,
cross-sectional design was used to investigate the potential association and to identify
characteristics that differentially affect the odds of association between groups. Finally,
the study evaluated the prevalence of CVD when this comorbidity exists. The purpose of
this chapter is to present results and findings of the study.
Using existing data, the analysis was performed after adjusting for potential
confounding factors (age, gender, ethnicity, education, and smoking status). The
following hypotheses were tested to achieve the objectives of the study:
Hypothesis 1: Patients with T2DM do have a statistically significant increased
prevalence of having RA compared to patients without T2DM.
Hypothesis 2: Patients with T2DM do have a statistically significant different
prevalence of RA compared to patients without T2DM, based on specific demographic,
lifestyle, or clinical characteristics.
Hypothesis 3: Patients with RA do have a statistically significant different
prevalence of T2DM compared to patients without RA, based on specific demographic,
lifestyle, or clinical characteristics.
Hypothesis 4: Patients with T2DM and concomitant RA do have a statistically
significant increased prevalence of CVD compared to patients with T2DM and no
presence of RA and patients with RA and no presence of T2DM.
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Chapter 4 provides a characterization of the study population and summarizes the
results of the analyses for the previously described investigation.
Analyses
The investigation used the continuous NHANES Data, from 1999 to 2012,. in
which 71,917 U.S. noninstitutionalized individuals participated in this survey. Of those,
68,705 completed both the interview and the examination portions, yielding overall
response rates of 96%. Of this number, 36,071 who were at least 20 years old were asked
RA survey questions. As part of the criteria for this study, any females with evidence of
pregnancy were excluded from the sample (3,850); this decreased the sample to 32,221.
Of that number, 3,689 participants self-reported diabetes. After applying study selection
criteria for diagnosed T2DM (see Chapter 3), 3,572 adult participants with diagnosed
T2DM were used in the current study. Similarly, 8,601 reported having some type of
arthritis in general and 1,705 participants met the criteria for diagnosed RA (see Figure
6).
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Figure 6. Study population.
Tables 2 through 7 (shown later in this chapter) presents the socio-demographic
and health-related characteristics of study participants in the 1999 to 2012 NHANES data
sets. As presented in Figure 6, the population consisted of four groups; participants with
evidence of T2DM and RA (n = 396 patients); participants with evidence of RA but no
T2DM (n = 1309); participants with evidence of T2DM but no evidence of RA (n =
3176); and participants with no evidence of T2DM nor RA (n = 26,607). Differences
between the cohorts were assessed by F-tests and t-tests for continuous variables, and chisquare statistics for categorical variables. The primary hypothesis of the current study
(Objective 1) was tested at two-tailed p < 0.05. All bivariate were considered exploratory
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in nature. The overall p-value (Groups 1 = 2 = 3 = 4) was examined first; only if overall
p-value was significant, then additional pairwise p-values were evaluated. If no
significant in overall test; pairwise p-values were not considered. All statistical analyses
utilized SAS version 9.2 (SAS Institute) SURVEY procedures that accounted for the
complex survey characteristics of NHANES, such as strata, weighting, and clustering of
observations.
Demographic Characteristics
Table 2 describes the demographic characteristics evaluated in the research
including age, gender, race/ethnicity, education level, and poverty level.
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Table 2.
Demographic Characteristics of Population by T2DM and RA Status

Variable

Level

Gender

M

Gender

F

Age at
screening
Ethnicity

All Hispanic

Ethnicity

NH White

Ethnicity

NH Black

Ethnicity

Other

Education
Education
Education

th

Less than 9
grade
9-11th grade

Education

HS
grad/equivalen
t
Some college

Education

College grad

Poverty
index ratio

Group 1
TD2M+/RA+
Mean or PCT
(95% CI)

Group 2
TD2M+/RAMean or PCT
(95% CI)

Group 3
TD2M-/RA+
Mean or PCT
(95% CI)

Group 4
TD2M-/RAMean or PCT
(95% CI)

40.40
(34.7-46.1)
59.60
(53.9-65.3)
.
64.26
(62.3-66.2)
.
12.06
(7.8-16.3)
57.07
(49.5-64.6)
25.52
(20.3-30.7)
5.35
(2.0-8.7)
.
19.50
(13.7-25.3)
21.18
(16.2-26.6)
27.84
(21.3-34.4)

54.57
(52.4-56.77)
45.43
(43.2-47.6)
.
60.64
(60.0-61.3)
.
14.50
(11.6-17.4)
62.54
(59.1-66.0)
15.44
(13.0-17.9)
7.52
(5.9-9.2)
.
14.05
(12.5-15.6)
16.79
(15.1-18.5)
25.58
(23.32-28.0)

46.45
(43.1-49.8)
53.55
(50.2-56.9)
.
57.13
(56-58.3)
.
8.54 (6.210.9)
72.71 (69.376.1)
14.64 (12.317.0)
4.11 (2.6-5.6)

53.30
(52.7-53.9)
46.70
(46.1-47.3)
.
44.61
(44.1-45.1)
.
13.17
(11.4-14.9)
70.93
(68.6-73.2)
10.40
(9.2-11.6)
5.50
(4.9-6.4)
.
5.96
(5.5-6.4)
12.13
(11.4-12.9)
24.32
(23.4-25.3)

24.60
(18.4-30.7)
6.87
(3.4-10.4)
.
2.19
(2.0-2.4)

26.77
(24.3-29.2)
16.80
(14.7-19.0)
.
2.62
(2.5-2.7)

29.28 (25.632.9)
13.87 (11.116.6)
.
2.62 (2.5-2.8)

.
9.60 (7.811.4)
17.52 (14.820.3)
29.73 (26.533.0)

30.65
(29.7-31.6)
26.93
(25.4-28.5)
.
3.02
(3.0-3.1)

Note: F = female; Grad = graduate; HS = high school; M = male; N = no; NH = nonHispanic; PCT = percent; Y=yes.
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Table 3.
Significance of Differences Among Groups for Demographic Characteristics of
Population by T2DM and RA Status

Variable

1=2=3=4
pVal 1

1v2
pVal 2

1v3
pVal 3

1v4
pVal 4

2v3
pVal 5

2v4
pVal 6

3v4
pVal 7

Gender

<.0001

<.0001

0.0695

<.0001

<.0001

0.2736

0.0002

Age at
screening

<0.0001

0.00054

<0.000

<0.0001

<0.0001

<0.000

<0.0001

Ethnicity

<.0001

0.0005

<.0001

<.0001

<.0001

<.0001

<.0001

Education
level

<.0001

0.0012

0.0002

<.0001

0.0032

<.0001

<.0001

Poverty index
ratio

<0.0001

<0.0001

0.0006

<0.0001

0.90075

<0.000

<0.0001

Smoking
status

<.0001

0.4802

0.0658

0.0008

<.0001

<.0001

<.0001

Physical
disability

<.0001

0.0021

0.0024

<.0001

0.8131

<.0001

<.0001

Mental
disability

<.0001

0.0336

0.2635

<.0001

0.2069

<.0001

<.0001

Disability

<.0001

0.0033

0.0104

<.0001

0.9247

<.0001

<.0001

Note: pVal = p value; chi-square test was used to evaluate nominal, ordinal, and
categorical variables. For continuous variables with interval and ratio level data, t-tests
was used; Groups numbers based on table 2.
Gender: Those groups with participants with positive evidence to RA were
predominantly females (T2DM and RA: 59.6% [95% CI: 53.9% - 65.3%; p < .0001 ];
RA and no T2DM: 53.6% [95% CI: 50.3% - 56.9%; p < .0001]) in comparison with
those with negative evidence of RA (T2DM [-] and RA [-]: 46.7% (95% CI: 46.1% -
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47.3%; p < .0001); RA [-] and T2DM [+]: 45.4% (95% CI: 43.2% - 47.6%; p < .0001),
which is consistent with the literature available related to RA.
Age: Participants with T2DM and no RA tended to be older (60.6 [95% CI: 59.9 –
61.3; p < .0001) than participants with RA and no T2DM (57.1 [95% CI: 56.0 – 58.3; p
< .0001]); however, participants with both conditions combined were found to be even
older (64.3 [95% CI: 62.3 – 66.1; p < .0001]) than those with only one condition or those
with no evidence of RA or T2DM (44.6 [95% CI: 44.1 – 45.1; p < .0001]).
Education: Participants with lower level of education (“less than a high school
education”) were more likely to have evidence of disease (T2DM and RA [40.7% (95%
CI: 34.3% -47.1%; p < .0001)], T2DM alone [30.8% (95% CI:28.7% – 33.0% ; p
< .0001)], and RA alone [27.1% (95% CI:23.9% – 30.4% ; p < .0001)]) versus the group
of participants with no evidence of T2DM or RA (18.1% (95% CI: 17.1% – 19.1%; p <
.0001)). Education was not significantly different between individual diseases or even
comparable to those with both conditions. See Figure 7.
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Education: Less than High School
Percenta ge +/- 95% Confidence Interval

Education: Less than High School
50
45
40
35
30
25
20
15
10
5
0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 7. Distribution of patients with “less than high school” education by diabetes and
RA status in the United States (1999 – 2012).
Race / Ethnicity: The proportion of non-Hispanic black participants was higher in
the group with this comorbidity (25.5% [95% CI: 20.3% – 30.7%; p <.0001]) than the
group with only T2DM or only RA (15.4% [95% CI: 13.0% – 17.9%; p <.0001]); 14.6%
(95% CI: 12.3% – 17.1% ; p <.0001), respectively). No significant difference was found
in participants with this comorbid conditions within Hispanics or non-Hispanic whites.
See Figure 8, 9, and 10.
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Ethnicity: Non Hispanic Blacks
Percenta ge+/- 95% Confidence Interval

Ethnicity: Non Hispanic Blacks
35
30
25
20
15
10
5
0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 8. Distribution of patients by ethnicity (non-Hispanics Blacks) among patients by
diabetes and RA status in the United States (1999-2012).

Ethnicity: Hispanics
Percentage+/- 95% Confidence Interval

Hispanics
20
18
16
14
12
10
8
6
4
2
0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 9. Distribution of patients by ethnicity (Hispanics) among patients by diabetes and
RA status in the United States (1999 – 2012).
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Ethnicity: Non Hispanic Whites
Percentage+/- 95% Confidence Interval

Ethnicity: Non Hispanic Whites
80
70
60
50
40
30
20
10
0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 10. Distribution of patients by ethnicity (non-Hispanics Whites) among patients
by diabetes and RA status in the United States (1999 – 2012).
PIR: Income relative to the poverty index on the group of this comorbidity was
lower (2.2 [95% CI: 2.0 – 2.4 ; p <.0001]) than those with only 1 condition (T2DM alone:
2.6 [95% CI: 2.5 – 2.7 ; p <.0001]; RA alone: 2.6 [95% CI: 2.5 – 2.8 ; p <.0001]); similar
in those with only one condition; and higher in those participants with no evidence of RA
or T2DM.
Lifestyle Characteristics
Tables 4 and 5 describes the lifestyle characteristics evaluated in the research
including smoking status, disability and work functioning.
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Table 4.
Lifestyle Characteristics of Population by T2DM and RA Status: Bivariate and
Multivariate Analysis

Variable

Level

Smoking
status
Smoking
status
Smoking
status

Nonsmoker
Past Smoker
Current
Smoker

Physical
disability
Physical
disability

Y

Mental
disability
Mental
disability

Y

Disability

Y

Disability

N

Work
functioning
Work
functioning

N

N

N

Y

Group 1
TD2M+/RA+
Mean or PCT
(95% CI)

Group 2
TD2M+/RAMean or PCT
(95% CI)

Group 3
TD2M-/RA+
Mean or PCT
(95% CI)

Group 4
TD2M-/RAMean or PCT
(95% CI)

44.24
(37.1-51.4)
33.95
(26.5-41.5)
21.81
(15.1-28.5)
.
26.50
(20.9-32.1)
73.50
(67.9-79.1)
.
19.46
(13.4-25.5)
80.55
(74.5-86.6)
.
17.45
(11.7-23.2)
82.55
(76.8-88.4)

48.20
(45.9-50.5)
33.58
(31.5-25.7)
18.22
(16.6-19.8)
.
17.56
(15.7-19.5)
82.44
(80.6-84.3)
.
13.47
(11.6-15.3)
86.53
(84.7-88.4)
.
10.32
(8.6-12.0)
89.68
(88.0-91.4)

38.43
(34.8-42.1)
30.78
(27.7-33.9)
30.79
(27.3-34.4)
.
17.97
(14.8-21.1)
82.03
(78.9-85.2)
.
15.63
(12.6-18.7)
84.37
(81.3-87.4)
.
10.45
(8.2-12.7)
89.55
(87.3-91.8)

52.80
(51.6-54.0)
21.52
(20.7-22.4)
25.68
(24.7-26.6)
.
7.63
(7.1-8.1)
92.37
(91.9-92.9)
.
9.42
(8.9-9.9)
90.58
(90.1-91.1)
.
3.68
(3.3-4.0)
96.32
(96.0-96.7)

55.78
(48.6-63.0)
44.22
(37.0-51.4)

73.36
(70.9-75.9)
26.64
(24.2-29.1)

71.88
(67.9-75.9)
28.12
(24.1-32.1)

91.46
(90.7-92.3)
8.54
(7.7-9.4)
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Table 5
Significance of Differences Among Groups for Demographic Characteristics of
Population by T2DM and RA Status
1=2=3=4
pVal 1

1v2
pVal 2

1v3
pVal 3

1v4
pVal 4

2v3
pVal 5

2v4
pVal 6

3v4
pVal 7

Smoking
status

<.0001

0.4802

0.0658

0.0008

<.0001

<.0001

<.0001

Physical
disability

<.0001

0.0021

0.0024

<.0001

0.8131

<.0001

<.0001

Mental
disability

<.0001

0.0336

0.2635

<.0001

0.2069

<.0001

<.0001

Disability

<.0001

0.0033

0.0104

<.0001

0.9247

<.0001

<.0001

Work
functioning

<.0001

<.0001

<.0001

<.0001

0.5106

<.0001

<.0001

Variable

Note: pVa l= p value; chi-square test was used to evaluate nominal, ordinal, and
categorical variables. For continuous variables with interval and ratio level data, t-tests
was used; Groups numbers based on table 4.
Smoking: Smoking cigarettes is a factor associated with T2DM as well as RA.
Interestingly, based on the study results, the proportion of current smokers was lower
within those participants with positive diagnosis to T2DM and RA (21.8% current
smokers [95% CI: 15.1% - 28.5%; p<.0001]), particularly within those with only T2DM
(18.2% [95% CI:16.6% – 19.8% ; p <.0001]) compare with those participants with
compare with those participants with no T2DM or RA (25.68% [95% CI:24.7% – 26.6%
; p <.0001]). However, considering the past smokers, participants with positive diagnosis
of both conditions had a higher likelihood of having been past smokers (34.0% [95% CI:
26.5% – 41.5% ; p < .0001]) or individual diseases (T2DM alone: 33.6% [95% CI: 31.5%
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- 35.7% ; p < .0001]); RA alone: 30.8% (95% CI: 27.7% - 33.9% ; p < .0001]) in
comparison to those with no T2DM or RA (21.5% [95% CI: 20.7% - 22.4% ; p < .0001]).
See Figure 11.

Smoking
Nonsmoker

21.81

18.22

33.95

33.58

44.24

48.20

T2DM+/RA+

Past Smoker

30.79

Current Smoker

25.68
21.52

30.78

T2DM+/RA-

38.43

T2DM-/RA+

52.80

T2DM-/RA-

Figure 11. Distribution of patients by “smoking status” among patients by diabetes and
RA status in the United States (1999–2012).
Disability: A significant proportion of participants with T2DM and RA report
disability. In the current study, disability was defined based on how many days during the
past 30 days your physical or mental health was not good preventing you from doing
your usual activities, such as self-care, work, school, or recreation. Refer to Chapter 3 for
a complete definition of disability. The proportion of participants with physical disability
in participants with positive evidence of RA alone and positive evidence of T2DM alone
was higher than the normal population but similar between individual diseases (17.6%
[95% CI:15.7% – 19.5% ; p < .0001]; 18.0% [95% CI: 14.9% – 21.1%; p < .0001]);
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however, the proportion of physical disability in participants with both conditions was
significantly higher (26.5% [95% CI: 20.9% – 32.1%; p < .0001]). It was found that
mental disability is more prevalent in participants with RA alone (15.6% [95% CI: 12.6%
– 18.7% ; p < .0001]) versus participants with T2DM alone (13.5% [95% CI: 11.7% –
15.3% ; p <.0001]); however, the proportion of mental disability was significantly higher
in participants with both conditions (19.5% [95% CI:13.4 – 25.5 ; p < .0001]) In general,
participants with both conditions (T2DM and RA) had higher probabilities of being
physically and mentally disabled (17.5% [95% CI: 11.7% – 23.2%; p < .0001]) versus
participants with T2DM alone (10.3% [95% CI: 8.6% – 12.0%; p < .0001]) or
participants with RA alone (10.5% [95% CI: 8.2% – 12.7%; p <.0001]). See Figure 12,
13 and 14.

Disability (Mental and Physical)
Disability (Mental and Physical)
Percentage+/- 95% Confidence Interval
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T2DM-/RA-
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Figure 12. Distribution of patients by general disability (mental & physical) among
patients by diabetes and RA status in the United States (1999–2012).
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Percentage+/- 95% Confidence Interval
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Figure 13. Distribution of patients by physical disability among patients by diabetes and
RA status in the United States (1999–2012).
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Mental Disability

Mental Disability
Percentage+/- 95% Confidence Interval
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Figure 14. Distribution of patients by mental disability among patients by diabetes and
RA status in the United States (1999–2012).
Work Functioning: As an important factor to consider related to the previous
characteristic (disability), this study also evaluated the ability to work. Similarly, the
proportion of participants that was not able to work was higher within the group of
participants with both conditions combined (44.2% [95% CI: 37.0% – 51.4%; p <.0001])
versus the group of participants with presence of only one of the conditions; 26.6 % (95%
CI: 24.2% – 29.1%; p < .0001), and 28.1% (95% CI: 24.3% – 32.1%; p < .0001) for
T2DM and RA, respectively. In comparison, the group of participants with no evidence

99
of any of these diseases, the inability to work was only 8.5% (95% CI: 7.7% – 9.4%; p <
.0001). See Figure 15.

Work Functioning
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Figure 15. Distribution of patients by work functioning among patients by diabetes and
RA status in the United States (1999 – 2012).
Clinical Characteristics
Clinical characteristics evaluated in the present investigation were: hypertension,
blood pressure levels, BMI, lipid levels (HDL/LDL, TC), CRP, glucose, HbA1c, and the
use of some medications commonly used to treat arthritis. Tables 6 and 7 describe the
clinical characteristics assessed in the research.
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Table 6.
Clinical Characteristics of Population by T2DM and RA Sstatus: Bivariate and
Multivariate Analysis
Group 1
TD2M+/RA+
Variable

Mean or PCT
(95% CI)
32.38
(31.5-33.2)

Obesity
classification
Obesity
classification
Obesity
classification

Normal weight

16.29 (11.9-20.7)

Overweight

25.03 (19.7-30.3)

Obese

58.68 (52.2-65.1)

Hypertension

Normal

.
28.42 (22.3-34.5)

Hypertension

Prehypertension

45.41 (39.1-51.7)

Hypertension

Hypertension

26.17 (20.8-31.5)

Diastolic blood
pressure
HDL

LDL

Total
cholesterol
Glucose

HbA1c

Group 3
TD2M-/RA+

Mean or PCT
(95% CI)
32.38
(32.0-32.8)

Mean or PCT
(95% CI)
29.06
(28.5-29.6)

Level

BMI

Systolic blood
pressure

Group 2
TD2M+/RA-

.
131.97
(129.7-134.2)
.
63.98
(61.3-66.7)
.
46.63
(44.9-48.4)
.
106.59
(97.37-115.8)
.
191.33
(184.6-198.0)
.
149.64
(142.0-157.3)
.
7.08
(6.9-7.3)
.

13.82
(12.2-15-4)
27.86
(25.7-30.0)
58.32
(55.6-61.0)
.
26.78
(24.4-29.1)
50.97
(48.3-53.6)
22.25
(20.3-24.2)
.
132.00
(131.0-133.0)
.
68.76
(68.0-69.6)
.
47.16
(46.5-47.8)
.
105.32
(102.6-108.0)
.
191.67
(188.9-194.5)
.
158.13
(153.6-162.6)
.
7.32
(7.2-7.4)
.

28.65
(245.5-31.9)
32.21
(29.2-35.2)
39.14
(35.7-42.6)
.
35.42
(31.6-39.2)
48.50
(44.9-52.1)
16.08
(13.7-18.5)
.
128.01
(126.5-129.6)
.
70.51
(69.4-71.6)
.
52.92
(51.7-54.1)
.
118.60
(114.8-122.4)
.
202.73
(199.4-206.0)
.
101.15
(99.6-102.7)
.
5.48
(5.4-5.5)

Group 4
TD2M-/RAMean or PCT
(95% CI)
27.92
(27.8-28.1)
35.03
(34.0-36.1)
34.94
(34.1-35.8)
30.04
(29.2-31.0)
.
47.66
(46.6-48.7)
44.62
(43.6-45.6)
7.72
(7.3-8.1)
.
121.67
(121.3-122.1)
.
71.31
(71.0-71.7)
.
52.47
(52.1-52.8)
.
118.00
(117.1-118.9)
.
198.46
(197.7-199.2)
.
98.54
(98.1-99)
.
5.36
(5.35-5.37)

.
(table continues)

101
Group 1
TD2M+/RA+
Variable

Group 3
TD2M-/RA+

Level
Mean or PCT
(95% CI)

CRP

Analgesics

N

Analgesics

Y

Antirheumatic
drugs
Antirheumatic
drugs

N

Glucocorticoid
s
Glucocorticoid
s

Group 2
TD2M+/RA-

Y

N
Y

0.75
(0.60-0.91)
.
83.11
(77.8-88.4)
16.89
(11.6-22.2)
.
97.76
(96.6-98.9)
2.24
(1.1-3.4)
.
94.39
(91.2-97.6)
5.61
(2.5-8.8)

Mean or PCT
(95% CI)
0.56
(0.52-0.60)
.
91.70
(90-.2-93.2)
8.30
(6.8-9.8)
.
99.96
(99.9-100)
0.04
(0-0.1)
.
97.38
(96.6-98.1)
2.63
(1.9-3.4)

Mean or PCT
(95% CI)
0.59
(0.54-0.65)
.
85.89
(83.7-84.1)
14.11
(11.9-16.2)
.
96.25
(96.7-97.8)
3.75
(2.2-5.3)
.
93.69
(92.1-95.3)
6.31
(4.7-7.9)

Group 4
TD2M-/RAMean or PCT
(95% CI)

0.38
(0.37-0.40)
.
95.93
(95.6-96.3)
4.07
(3.7-4.4)
.
99.85
(99.8-99.9)
0.15
(0.1-0.2)
.
98.74
(98.6-98.9)
1.26
(1.1-1.4)
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Table 7.
Significance of Differences Among Groups for Demographic Characteristics of
Population by T2DM and RA Status

Variable

1=2=3=
4
pVal 1

1v2
pVal 2

1v3
pVal 3

1v4
pVal 4

2v3
pVal 5

2v4
pVal 6

3v4
pVal 7

BMI

<0.0001

1

<0.000

<0.0001

<0.0001

<0.000

<0.0001

Obesity
classification

<.0001

0.4448

<.0001

<.0001

<.0001

<.0001

<.0001

Hypertension

<.0001

0.2396

0.0005

<.0001

<.0001

<.0001

<.0001

Systolic blood
pressure

<0.0001

0.97822

0.004

<0.0001

0.00015

<0.000

<0.0001

Diastolic
blood pressure

<0.0001

0.00065

<0.000

<0.0001

0.00138

<0.000

0.10921

HDL

<0.0001

0.58266

<0.000

<0.0001

<0.0001

<0.000

0.43366

LDL

<0.0001

0.80551

0.0173

0.01786

<0.0001

<0.000

0.75905

Total
cholesterol

<0.0001

0.92953

0.0045

0.03891

<0.0001

<0.000

0.01236

Glucose

<0.0001

0.06572

<0.000

<0.0001

<0.0001

<0.000

0.00155

HbA1c

<0.0001

0.02179

<0.000

<0.0001

<0.0001

<0.000

<0.0001

CRP

<0.0001

0.02092

0.0716

<0.0001

0.43273

<0.000

<0.0001

Analgesics

<.0001

0.0001

0.3396

<.0001

<.0001

<.0001

<.0001

Antirheumatic
drugs

<.0001

<.0001

0.1235

<.0001

<.0001

0.1576

<.0001

Glucocorticoid

<.0001

0.0151

0.7038

<.0001

<.0001

<.0001

<.0001

Note: pVal = p value; chi-square test was used to evaluate nominal, ordinal, and
categorical variables. For continuous variables with interval and ratio level data, t-tests
was used; Groups numbers based on Table 6.
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Body Max Index (BMI). BMI was assessed as a continuous and also categorical
variable. As a continuous variable, BMI was higher in those participants with the
presence of T2DM. This was similar between those participants with or without RA
(T2DM and RA [32.4 (95% CI: 31.5 – 33.2 ; p <.0001)]; T2DM with no RA [32.4 (95%
CI: 32.0 – 32.9; p <.0001)]). However; BMI was lower in the group of participants with
RA alone or participants with no presence of RA or T2DM (29.1 [95% CI: 28.5 – 29.6; p
<.0001] and 27.9 [95% CI: 27.8 – 28.1 ; p <.0001], respectively). Participants with
T2DM and RA had similar BMI as those with T2DM alone.
Using weight classification based on BMI levels (categorical variable), where
normal weight was defined as BMI of 25 kg/m2 or less; overweight as BMI of 25 to
29.9 kg/m2, and obesity as BMI of 30 kg/m2 and above, it was found that the proportion
of obese participants was higher in the group of participants with presence of T2DM with
or without RA (58.7% [95% CI: 52.2% – 65.1%; p < .0001], 58.3% [95% CI: 55.6% –
61.0% ; p < .0001], respectively) than those with presence of RA alone (39.1% [95% CI:
35.7% – 42.6% ; p < .0001]) or no presence of RA or T2DM (30.0% [95% CI: 29.2% –
31.0% ; p < .0001]). See Figure 16.
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Weight Classification: Obese (BMI > 30)
Weight Classification: Obese (BMI >30)
Percentage+/- 95% Confidence Interval

70
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0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 16. Distribution of obese patients (BMI >30) among patients by diabetes and RA
status in the United States (1999 – 2012).
The cardiovascular marker profile was very similar between participants with
T2DM and RA versus T2DM and no RA, yet they differed with RA and no T2DM (and
the group of no RA or T2DM).
Hypertension/Blood Pressure: Consistent with the literature, hypertension is
highly predominant in participants with T2DM and comorbid RA (26.2% [95% CI:
20.8% – 31.5%; p < .0001]) as well as in participants with T2DM alone (22.3 [95% CI:
20.3% – 24.2% ; p < .0001]) in comparison with participants with no T2DM or
participants with negative evidence of this comorbidity (7.7% [95% CI:7.3% – 8.1% ; p
< .0001]). There was no significant difference in the proportion of participants with
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hypertension between the group of participants with T2DM and RA in comparison with
T2DM and no RA; however, participants with only RA (16.1% [95% CI: 13.7% – 18.5%;
p < .0001]) were less likely to have hypertension in comparison to those with only T2DM
or with those participants with both conditions. The proportion of hypertension within
participants with RA alone (16.1% [95% CI: 13.7% – 18.5%; p < .0001]) was
significantly higher in comparison with participants with no evidence of RA or T2DM
(7.7% [95% CI: 7.3% – 8.1% ; p < .0001]). See Figure 17.

Hypertension

Hypertension
Percentage+/- 95% Confidence Interval

35
30
25
20
15
10
5
0
Group
T2DM+/RA+

T2DM+/RA-

T2DM-/RA+

T2DM-/RA-

Figure 17. Distribution of patients with hypertention among patients by diabetes and RA
status in the United States (1999 – 2012).
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The average systolic blood pressure for participants with T2DM and RA as well
as participants with T2DM and no RA was 132 (95% CI: 129.7 -134.2; p < .0001) and
132 (95% CI: 131.0 – 133.0; p < .0001), respectively; for participants with RA and no
T2DM was128 (95% CI: 126.5 - 130 ; p < .0001); and for participants with no presence
of RA or T2DM was122 (95% CI: 121.3 – 122.1 ; p < .0001). The average diastolic
blood pressure for participants with T2DM and RA was 64 (95% CI: 61.3 – 66.7; p
< .0001); for participants with T2DM and no RA was 69 (95% CI: 68 – 70 ; p < .0001);
for participants with RA and no T2DM as well as for participants with no presence of RA
or T2DM was 71 (95% CI: 69.4 – 71.6 ; p < .0001) and 71 (95% CI: 71 – 71.7; p <
.0001), respectively.
Lipids: TC was more elevated in participants with RA alone (202.7 [95% CI:
199.4 – 206.0 ; p < .0001]) in comparison with participants with both conditions, T2DM
and RA, and participants with T2DM alone (191.3 [95% CI: 184.6 – 198.0 ; p < .0001]
and 191.7 [95% CI: 188.9 – 194.5 ; p < .0001], respectively).
Glucose/HbA1c: The mean glucose was more elevated in those participants with
T2DM alone (158.1 [95% CI: 153.6 – 162.6 ; p <.0001]) and participants with both
conditions (149.6 [95% CI: 142.0 – 157.3 ; p < .0001]) versus those participants with no
evidence of T2DM (101.2 [95% CI: 99.6 – 102. 7; p < .0001]). Similar patterns were
found with HbA1c with a mean value of 7% for participants with T2DM versus a mean
value of approximately 5% for participants with no evidence of T2DM. No difference
was found in glucose for those with this comorbidity.
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CRP levels were similar within patients with T2DM (.56 [95% CI: 0.52 – 0.6; p
< 0.0001]) and RA alone (.59 [95% CI: 0.54 – 0.65; p < 0.0001]); however, higher
among patients with both conditions (.75 [95% CI: 0.60 – 0.91; p < 0.0001]) and lower
than those participants with no evidence of RA or T2DM (.38 [95% CI: 0.37 – 0.40; p
< 0.0001]).
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Among all included participants (n = 31,488), the prevalence of T2DM was 7.6%
(95% CI: 7.2% - 8.0% ; p < .0001) and the prevalence of RA was 4.0% (95% CI: 3.7% 4.3% ; p < .0001). For the primary objective of the present study, the analysis
investigated the cross-sectional association between T2DM and RA using a logistic
regression with T2DM as the independent variable and RA as the dependent variable.
The analysis included a description of variables and crude and adjusted prevalence of RA
for patients with and without diabetes. Adjusted ORs of RA were determined considering
predetermined confounding factors based on previous research including age, sex,
race/ethnicity, education, and smoking. Prevalence of T2DM was also calculated using
the same analysis. Results af these analysis is shown in Tables 8 to 11.
Table 8.
Prevalence of RA Within U.S. Patients with T2DM; Patients with No Diagnosis of
T2DM; and the General Population
T2DM

RA

T2DM (+)
T2DM (-)
All

RA (+)
RA (+)
RA (+)

Frequency

Percent

Std error

396
1309
1705

9.0144
3.6222
4.034

0.5806
0.1433
0.1411

Note: (+) = positive; (-) = negavive

95% CI
Lower
Upper
7.88
10.15
3.34
3.90
3.76
4.31

p-value
<0.0001
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Table 9.
Odd Ratios of RA from Multivariate Llogistic Regression Model
Variable
Diabetes
Gender
Age
Ethnicity

Odds Ratio

OR 95% CI
Lower
Upper
1.229
1.711
1.147
1.479
1.035
1.044
0.616
1.256
1.159
2.408
0.701
1.438
0.979
1.501

Education

T2DM vs not T2DM
F vs M
Per 1 year increase
All Hispanic vs Other
NH black vs other
NH white vs other
9-11th grade vs some College

1.450
1.302
1.040
0.879
1.671
1.004
1.213
0.564

0.452

0.703

1.115

0.924

1.346

1.212

0.932

1.575

Smoking
Status

College graduate vs some
College
High school Grad/equivalent
vs some College
Less than 9th grade vs some
college
Current smoker vs past
smoker

1.368

1.139

1.643

0.730

0.616

0.865

Nonsmoker vs past smoker

p-value
<.0001
<.0001
<.0001
<.0001

<.0001

<.0001

Table 10.
Prevalence of T2DM within U.S. patients with RA; Patients with No Diagnosis of RA;
and the General Population
RA
Status

T2DM

RA (+)
RA (-)
All

T2DM (+)
T2DM (+)
T2DM (+)

Frequency
396
3176
3572

Percent

Std error

17.0646
7.2401
7.6365

1.0717
0.2067
0.2049

95% CI
Lower
Upper
14.96
19.17
6.83
7.65
7.23
8.04

p-value
<0.0001
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Table 11.
Odd Ratios of T2DM from Multivariate Logistic Regression Model
Variable
Diabetes
Gender
Age
Ethnicity

Education

Smoking
status

Odds Ratio

OR 95% CI
Lower
Upper
1.229
1.711
1.147
1.479
1.035
1.044
0.616
1.256
1.159
2.408
0.701
1.438
0.979
1.501

RA vs not RA
F vs M
Per 1 year increase
All Hispanic vs other
NH black vs other
NH white vs other
9-11th grade vs some college

1.450
1.302
1.040
0.879
1.671
1.004
1.213

College graduate vs some
college
High school grad/equivalent
vs some college
Less than 9th grade vs some
college
Current smoker vs past
smoker
Nonsmoker vs past smoker

0.564

0.452

0.703

1.115

0.924

1.346

1.212

0.932

1.575

1.368

1.139

1.643

0.730

0.616

0.865

p-value
<.0001
<.0001
<.0001
<.0001

<.0001

<.0001

The prevalence of RA among participants with T2DM was 9.0% (95% CI:7.9% 10.2% ; p <.0001), which was significantly higher than the prevalence of RA among
those participants without T2DM (3.6% [95% CI:3.3% - 3.9%; p < .0001]). See Figure
18. Considering the prevalence of T2DM among participants with and without RA, the
difference was significantly higher with a prevalence of 17.1% (95% CI: 15.0% - 19.2% ;
p <.0001) for those participants with RA versus 7.2% (95% CI: 6.8% – 7.7% ; p <.0001)
among those without RA (OR 2.64; 95% CI [2.24, 3.10]; p < .0001). See Figure 19. The
adjusted ORs for the cross-sectional association between RA and T2DM were 1.45 (95%
CI 1.29, 1.71; p < .0001). The results of the current study demonstrated that there was a
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strong association between RA and T2DM after adjusting for potential confounders as
shown in Tables 8 through 11.
The distribution of the dependent and independent variables are presented in the
figure below including both prevalence of RA (Figure 18) among participants with
T2DM and no evidence of T2DM and also prevalence of T2DM (Figure 19) among
participants with RA and no evidence of RA. Prevalence of individual diseases in the
general population is shown in both figures for illustration purposes.

Prevalence of RA
NHANES 1999 - 2012
12
Prevalence of RA
Percentage+/- 95% Confidence Interval

9.0 %
10
8
6
3.6 %

4.0 %

4
2
0
Group
T2DM (+)

T2DM (-)

General Population

Figure 18. Prevalence of RA among U.S. patients with T2DM; patients with no diagnosis
of T2DM; and the general population; NHANES 1999- 2012.
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Prevalence of T2DM
NHANES 1999 - 2012
Prevalence of RA
Percentage+/- 95% Confidence Interval

25
17.1 %
20

15

10

7.2 %

7.6 %

5

0
Group
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RA (-)

General Population

Figure 19. Prevalence of T2DM within patients with RA; patients with no diagnosis of
RA; and the general population; NHANES 1999 – 2012.
The next two hypotheses evaluated potential demographic, lifestyle, or clinical
characteristics that affect the odds of association of T2DM or RA within the population
groups. To evaluate the hypothesis and achieve objectives, chi-square tests were
performed to evaluate nominal, ordinal, and categorical variables. The chi-square test
evaluates the null hypothesis, which states that there is no significant difference between
the expected and observed result.
The secondary objective for the investigation was to identify what demographic,
lifestyle, or clinical characteristics are significantly associated with increased odds of RA
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by comparing prevalence of RA within T2DM in comparison with prevalence of RA
within participants with no presence of T2DM. To achieve the objective, participants
were identified within the subgroup of the presence of RA between participants with and
without T2DM. A logistic regression was performed using RA as the dependent variable,
which produced univariate odds. This analysis described characteristics that were
potentially statistically significantly different in prevalence of RA within patients with
T2DM in comparison with prevalence of RA within participants with no presence of
T2DM. The following characteristics were evaluated: demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability, smoking status,
and work functioning) and clinical (blood pressure levels, BMI, lipid levels [HDL/LDL,
TC], CRP, and use of antirheumatic medications.
Table 12 represents the ORs for RA within the group of participants with T2DM
and within those with no presence of T2DM. Table 3 shows that females, with or without
a diagnosis of T2DM, have increased odds of having RA (p < 0.0001; OR: 1.77; 1.32
respectively). This result was expected because it is well know that females in the general
population are more likely to have concomitant RA. Regarding ethnicity, increased odds
of RA among non-Hispanic blacks and decreased RA odds among all Hispanics were
consistent between T2DM and non-T2DM. In addition, both T2DM and non-T2DM
showed decreasing odds of RA as education level increased, as did increasing income
relative to the poverty index.
Though significant in both groups, increasing age had a larger impact on
increasing odds of RA in the non-T2DM group (OR: 1.04 per year; 95% CI: 1.04-1.05; p
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< 0.0001) compared to the T2DM group (OR: 1.02 per year; 95% CI: 1.01-1.03; p
= 0.0007).
Smoking Status: Also, smoking status appeared to be more associated with RA
among non-T2DM group than the T2DM group. For instance, past smokers in the nonT2DM group had 1.97 (95% CI: 1.64-2.35; p < 0.0001) greater odds of RA compared to
the same odds for the T2DM group of 1.10 (95% CI: 0.77-1.57; p = 0.59).
Disability: In view of disability, mental and physical disabilities were evaluated
and as expected, for both the T2DM and non-T2DM groups, lack of physical and mental
disabilities were associated with lower odds of having RA. Those with reduced work
functionality were also associated with RA diagnosis, but this had greater impact on the
non-T2DM group 4.19 (95% CI: 3.35-5.23; p < 0.0001) compared to the T2DM group of
2.18 (95% CI: 1.62-2.95; p < 0.0001).
Obesity: Compared to normal weight, obese individuals had 1.59 greater odds
(95% CI: 1.33-1.91; p < 0.0001) of having RA if they are non-T2DM, whereas no such
relationship was seen with T2DM (OR: 0.85; 95% CI: 0.59-1.23; p = 0.40). The same
relationship was observed with higher average systolic blood pressure, higher fasting
glucose, and higher HbA1c levels, which were associated with greater odds of RA in the
non-T2DM group, but was not statistically related to RA among the T2DM group.
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Table 12.
Univariate Odds Ratio of RA
Variables

OR
Estimate

Gender

1.377

Lower
95% CI
for OR
1.211

Age at screening

1.041

1.037

All Hispanics vs NH white
NH black vs NH white
Other vs NH white

0.692
1.538
0.769

Educ 9-11th grade vs less than 9th
grade
Educ college grad vs less than 9th
grade
Educ HS grad/ Equivalent vs less
than 9th grade
Educ some college vs less than 9th
grade

Overall
Upper
95% CI
for OR
1.565

p-value

OR
Estimate

Within T2DM Subgroup
Lower
Upper
95% CI
95% CI
for OR
for OR
1.379
2.279

p-value

<.0001

Within non-T2DM Subgroup
OR
Lower
Upper
Estimate
95% CI
95% CI
for OR
for OR
1.316
1.14
1.518

p-value

<.0001

1.772

0.0002

1.045

<.0001

1.021

1.009

1.033

0.0007

1.041

1.037

1.045

<.0001

0.564
1.347
0.548

0.849
1.757
1.079

0.0004
<.0001
0.1283

0.911
1.812
0.781

0.649
1.347
0.378

1.278
2.436
1.611

0.5895
<.0001
0.5027

0.633
1.373
0.729

0.509
1.195
0.5

0.787
1.578
1.063

<.0001
<.0001
0.1009

0.844

0.677

1.052

0.1319

0.908

0.585

1.411

0.6692

0.897

0.694

1.159

0.4059

0.281

0.223

0.353

<.0001

0.295

0.162

0.535

<.0001

0.32

0.243

0.422

<.0001

0.699

0.576

0.848

0.0003

0.784

0.494

1.245

0.3021

0.759

0.602

0.958

0.0202

0.544

0.437

0.679

<.0001

0.662

0.421

1.04

0.0733

0.594

0.454

0.775

0.0001

Poverty index ratio

0.844

0.811

0.877

<.0001

0.823

0.745

0.908

0.0001

0.86

0.822

0.899

<.0001

Poverty line at or below line vs
above line

1.327

1.117

1.576

0.0013

1.276

0.958

1.699

0.0954

1.308

1.073

1.594

0.0079

Current smoker vs nonsmoker
Past smoker vs nonsmoker

1.549
1.862

1.312
1.578

1.829
2.197

<.0001
<.0001

1.304
1.102

0.856
0.772

1.985
1.573

0.2163
0.5942

1.648
1.965

1.375
1.641

1.974
2.354

<.0001
<.0001

Physical disability (y vs n)

0.379

0.313

0.458

<.0001

0.591

0.419

0.832

0.0026

0.377

0.302

0.471

<.0001

Mental disability (y vs n)

0.553

0.455

0.673

<.0001

0.645

0.429

0.969

0.035

0.561

0.446

0.707

<.0001

Disability (y vs n)

0.33

0.265

0.411

<.0001

0.545

0.359

0.827

0.0043

0.327

0.254

0.421

<.0001

Work functioning (y vs n)

4.086

3.351

4.981

<.0001

2.183

1.617

2.948

<.0001

4.188

3.354

5.229
<.0001
(table continues)
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Variables

OR
Estimate

BMI

1.03

Lower
95% CI
for OR
1.02

Obesity vs normal weight
Overweight vs normal weight

1.664
1.135

1.407
0.977

Hypertension vs normal
Prehypertension vs normal

2.743
1.435

Systolic blood pressure

Overall
Upper
95% CI
for OR
1.039

p-value

OR
Estimate

Within T2DM Subgroup
Lower
Upper
95% CI
95% CI
for OR
for OR
0.981
1.019

<.0001

1

1.969
1.318

<.0001
0.0969

0.853
0.762

0.591
0.526

2.226
1.21

3.381
1.702

<.0001
<.0001

1.109
0.84

1.016

1.013

1.019

<.0001

Diastolic blood pressure

0.99

0.984

0.995

HDL

0.999

0.995

LDL

1

Total cholesterol

p-value

OR
Estimate

Within non-T2DM Subgroup
Lower
Upper
p-value
95% CI
95% CI
for OR
for OR
1.016
1.038
<.0001

1

1.027

1.232
1.104

0.3976
0.1506

1.593
1.127

1.33
0.951

1.909
1.336

<.0001
0.1671

0.762
0.599

1.612
1.176

0.5894
0.3096

2.804
1.462

2.227
1.219

3.531
1.754

<.0001
<.0001

1

0.994

1.006

0.9782

1.017

1.013

1.021

<.0001

0.0002

0.982

0.973

0.991

<.0001

0.995

0.989

1.001

0.0964

1.003

0.667

0.997

0.987

1.008

0.5877

1.002

0.997

1.006

0.4246

0.997

1.002

0.7474

1

0.993

1.007

0.9403

1.001

0.998

1.004

0.6691

1.002

1

1.003

0.0458

1

0.997

1.003

0.9301

1.002

1.001

1.004

0.0071

Glucose

1.005

1.004

1.007

<.0001

0.998

0.995

1

0.0841

1.006

1.003

1.009

<.0001

HbA1c

1.241

1.19

1.295

<.0001

0.915

0.843

0.993

0.0325

1.312

1.219

1.412

<.0001

CRP

1.203

1.155

1.252

<.0001

1.146

1.027

1.279

0.0146

1.198

1.147

1.252

<.0001

Use of analgesics (1 vs 0)

3.73

3.087

4.507

<.0001

2.246

1.452

3.472

0.0003

3.871

3.138

4.776

<.0001

Use of antirheumatics (1 vs 0)

24.829

15.014

41.06

<.0001

53.76

7.04

410.513

0.0001

25.333

14.782

43.415

<.0001

Use of glucocorticosteroids (1 vs
0)

4.784

3.587

6.379

<.0001

2.205

1.152

4.218

0.0169

5.269

3.852

7.207

<.0001
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The results in this case indicated that the following characteristics were important
in the association between T2DM and RA: gender, ethnicity, education, disability, and
work functioning.
Contrary to the second objective, for the third objective, the investigation used
participants within the subgroup of the presence of T2DM among patients with and
without RA to identify what demographic, lifestyle, or clinical characteristics are
significantly associated with increased odds of T2DM by comparing prevalence of
T2DM within participants with RA and prevalence of T2DM within participants with no
presence of RA. Similarly, a logistic regression was performed using T2DM as the
dependent variable and univariate ORs were determined. The analysis described potential
characteristics that were statistically significantly different in prevalence of T2DM
within patients with RA in comparison with prevalence of T2DM within participants
with no presence of RA. Characteristics evaluated were demographic (age, gender,
race/ethnicity, education level, and poverty level); lifestyle (disability, smoking status,
and work functioning); and clinical (blood pressure levels, BMI, lipid levels (HDL/LDL,
TC), presence of CVD, plasma glucose, and HbA1c).
Table 13 represents the ORs for T2DM within the group of participants with RA
and those with no presence of RA. The trends were very similar to Table 12. Among the
RA population, significant association of age, work functioning, obesity, hypertension,
prehypertension, and systolic blood pressure were found in the T2DM group, but the
odds were less than the non-RA population.
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Table 13.
Univariate Odds Ratio of T2DM
p-value

OR
Estimate

0.8249

0.781

Within RA Subgroup
Lower
Upper
95% CI
95% CI
for OR
for OR
0.597
1.022

1.056

<.0001

1.033

1.021

1.091
1.578
1.243

1.448
1.99
1.902

0.0015
<.0001
<.0001

1.799
2.221
1.659

0.584

0.502

0.681

<.0001

0.252

0.209

0.304

0.441

0.376

0.364

Poverty index ratio

Variables

OR
Estimate

Gender

1.01

Lower
95% CI
for OR
0.926

Age at screening

1.054

1.052

All Hispanics vs NH white
NH Black vs NH white
Other vs NH white

1.257
1.772
1.538

Overall
Upper
95% CI
for OR
1.101

Within non-RA Subgroup
Lower
Upper
p-value
95% CI
95% CI
for OR
for OR
0.96
1.154
0.2729

p-value

OR
Estimate

0.0716

1.053

1.045

<.0001

1.054

1.052

1.057

<.0001

1.284
1.649
0.783

2.52
2.991
3.516

0.0006
<.0001
0.1863

1.249
1.683
1.551

1.083
1.489
1.237

1.441
1.903
1.943

0.0022
<.0001
0.0001

0.595

0.357

0.992

0.0465

0.588

0.504

0.685

<.0001

<.0001

0.244

0.124

0.479

<.0001

0.265

0.219

0.32

<.0001

0.516

<.0001

0.461

0.276

0.77

0.0031

0.446

0.378

0.528

<.0001

0.312

0.425

<.0001

0.414

0.248

0.689

0.0007

0.371

0.314

0.437

<.0001

0.853

0.828

0.879

<.0001

0.832

0.749

0.925

0.0007

0.862

0.836

0.888

<.0001

Poverty line at or below line vs
above line

1.218

1.075

1.38

0.0019

1.173

0.839

1.64

0.3497

1.202

1.058

1.367

0.0049

Current smoker vs nonsmoker
Past smoker vs nonsmoker

0.784
1.681

0.698
1.514

0.88
1.866

<.0001
<.0001

0.615
0.958

0.397
0.662

0.952
1.387

0.0294
0.8209

0.778
1.709

0.689
1.532

0.878
1.908

<.0001
<.0001

Physical disability (yes vs no)

0.387

0.338

0.444

<.0001

0.608

0.433

0.852

0.0039

0.388

0.331

0.454

<.0001

Mental disability (yes vs no)

0.656

0.564

0.763

<.0001

0.767

0.479

1.227

0.2686

0.668

0.571

0.781

<.0001

Disability (yes vs no)

0.332

0.277

0.398

<.0001

0.552

0.345

0.884

0.0134

0.332

0.276

0.399

<.0001

Work functioning (yes vs no)

3.865

3.333

4.481

<.0001

2.026

1.519

2.703

<.0001

3.886

3.314

4.558

Educ 9-11th grade vs less than
9th grade
Educ college grad vs less than
9th grade
Educ HS grad/ equivalent vs less
than 9th grade
Educ some college vs less than
9th grade

<.0001
(table continues)
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Variables

OR
Estimate

BMI

1.089

Lower
95% CI
for OR
1.082

Obese vs normal weight
Overweight vs normal weight

4.765
1.966

4.14
1.705

Hypertension vs normal
Prehypertension vs normal

4.941
1.976

Systolic blood pressure

Overall
Upper
95% CI
for OR
1.096

p-value

OR
Estimate

Within RA Subgroup
Lower
Upper
95% CI
95% CI
for OR
for OR
1.042
1.088

<.0001

1.065

5.485
2.267

<.0001
<.0001

2.637
1.366

1.785
0.893

4.335
1.754

5.63
2.226

<.0001
<.0001

2.028
1.167

1.025

1.023

1.027

<.0001

Diastolic blood pressure

0.983

0.98

0.987

HDL

0.974

0.971

LDL

0.987

Total cholesterol

p-value

OR
Estimate

Within non-RA Subgroup
Lower
Upper
p-value
95% CI
95% CI
for OR
for OR
1.083
1.097
<.0001

<.0001

1.09

3.894
2.09

<.0001
0.1501

4.922
2.022

4.246
1.746

5.705
2.341

<.0001
<.0001

1.364
0.836

3.015
1.63

0.0005
0.3648

5.13
2.032

4.463
1.791

5.897
2.306

<.0001
<.0001

1.009

1.003

1.015

0.0027

1.026

1.024

1.028

<.0001

<.0001

0.975

0.965

0.984

<.0001

0.985

0.981

0.989

<.0001

0.978

<.0001

0.973

0.963

0.983

<.0001

0.975

0.971

0.978

<.0001

0.985

0.99

<.0001

0.987

0.979

0.996

0.0034

0.987

0.985

0.99

<.0001

0.996

0.994

0.997

<.0001

0.993

0.988

0.998

0.0099

0.996

0.994

0.998

<.0001

Glucose

1.053

1.047

1.06

<.0001

1.058

1.044

1.072

<.0001

1.052

1.046

1.059

<.0001

HbA1c

7.509

6.403

8.805

<.0001

8.35

4.946

14.096

<.0001

7.352

6.232

8.673

<.0001

CRP

1.201

1.147

1.258

<.0001

1.131

1.001

1.279

0.0489

1.195

1.14

1.254

<.0001

Use of analgesics (1 vs 0)

2.15

1.758

2.629

<.0001

1.237

0.798

1.916

0.3417

2.132

1.714

2.653

<.0001

Use of antirheumatics (1 vs 0)

0.848

0.494

1.456

0.5496

0.588

0.298

1.161

0.1261

0.279

0.042

1.855

0.1865

Use of glucocorticosteroids (1 vs
0)

2.032

1.536

2.688

<.0001

0.882

0.46

1.689

0.7048

2.108

1.555

2.859

<.0001
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The purpose of the fourth objective was to determine the prevalence of CVD
among participants with comorbid T2DM and RA in comparison to participants with
T2DM and RA independently and those with no evidence of T2DM or RA. The
prevalence and adjusted ORs for the prevalence of CVD in participants with comorbid
T2DM and RA was determined after adjusting for potential confounders (age, gender,
ethnicity, education, and smoking status). Logistic regression assessed the interaction of
RA and T2DM (independent variables) to determine if therelationship to CVD
(dependent variable) has a multiplicative effect on odds of CVD (significant interaction)
or whether their combination acts as two independent risk factors (nonsignificant
interacton).
Table 14.
Prevalence of CVD Within U.S. Patients by T2DM and RA Status; NHANES 1999-2012
CVD
Status
CVD (+)

T2DM
T2DM(+)/RA(+)
T2DM(+)/RA(-)
T2DM(-)/RA(+)
T2DM(-)/RA(-)
All

Freq.

Percent

165/396
947/3169
303/1305
2294/26581
3709/31451

43.3971
28.9474
21.3305
6.45262
8.7681

95% CI
Lower
Upper
36.22
26.81
18.52
6.07
8.26

50.57
31.09
24.14
6.83
9.28

p-value

<0.0001

Note: Freq. = frequency.

Table 15.
Odd Ratios of CVD from Multivariate Logistic Regression Model
Variable
Diabetes

T2DM+/RA+ vs T2DM-/RAT2DM+/RA- vs T2DM-/RA-

Odds ratio
4.737
2.898

OR 95% CI
Lower
Upper
3.508 6.397
2.564 3.276

p-value
<.0001
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Gender
Age
Ethnicity

Education

Smoking
Status

T2DM-/RA+ vs T2DM-/RAF vs M
Per 1 year increase
All Hispanic vs other
NH Black vs other
NH White vs other
9-11th grade vs some college

2.091
0.701
1.075
0.645
0.969
1.025
1.333

1.769
0.629
1.071
0.485
0.725
0.791
1.129

2.471
0.780
1.079
0.858
1.294
1.328
1.574

College graduate vs some
college
High school grad/ equivalent
vs some college
Less than 9th grade vs some
college
Current smoker vs past
smoker
Nonsmoker vs past smoker

0.724

0.632 0.830

1.041

0.910 1.191

1.309

1.091 1.569

1.182

1.030 1.356

0.689

0.607 0.783

<.0001
<.0001
<.0001

<.0001

<.0001

Among all participants (n = 31,488), the prevalence of CVD was 8.8% ± 0.3%.
The prevalence of CVD among participants with comorbid T2DM and RA was 43.4% ±
3.7%, which was significantly higher than the prevalence of CVD among those
participants with T2DM alone (28.95% ± 1.1%) and among those participants with RA
alone (21.3 ± 1.4%). Prevalence and adjusted ORs for T2DM and RA independently were
consistent with previous research. Prevalence of CVD among participants with no
evidence of T2DM or RA was 6.5% ± 0.2. The adjusted OR of CVD in participants with
comorbid T2DM and RA was 4.74 (95% CI 3.51, 6.40; p < .0001) while the ORs for
T2DM and RA independently were 2.90 (95% CI 2.56, 3.28; p < .0001) and 2.09 (95%
CI 1.77, 2.47; p < .0001), respectively. The results of this study demonstrated that the
ORs of CVD among participants with comorbid T2DM and RA is approximately two
times the possibility of having CVD when participants have one of these conditions and
about four times the possibility of having CVD in comparison with those not having any
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of these conditions. CVD is definitely an important factor to consider when managing
participants with comorbid T2DM and RA. See Figure 20 for the distribution of the
prevalence of CVD in participants with T2DM and RA as well as the prevalence of CVD
in the individual diseases. Prevalence of CVD in the general population is shown for
demonstration purpose.

Figure 20. Prevalence of CVD among patients by diabetes and RA status in the United
States (1999 – 2012).
Summary
The statistical analyses of the current study data supported Hypotheses 1 through
4. These analysis included univariate, bivariate, and multivariate assessments of adults
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within the different groups: (a) T2DM and RA; (b) T2DM and no presence of RA; (c) RA
and no presence of T2DM; and (d) no presence of T2DM nor RA using NHANES data
from1999 to 2012. The results supported a significant association between comorbid
T2DM and RA. Prevalence of RA was significantly higher for those participants with
T2DM in comparison with the prevalence of RA in participants with no evidence of
T2DM. In addition, the prevalence of T2DM was higher in participants with RA versus
participants with no evidence of RA. The adjusted OR for the cross-sectional association
between RA and T2DM were 1.45 (95% CI: 1.23, 1.71; p < .0001). The results of this
study demonstrated a strong association between RA and T2DM, and that the prevalence
of CVD among participants with this comorbidity (T2DM and RA) was higher than those
having individual diseases and even higher comapared to the general population. The
ORs of CVD among participants with comorbid T2DM and RA was two times the
posibility when having one of these conditions and four times the possibility when not
having any of these conditions. CVD is an important factor to consider when managing
patients with comorbid T2DM and RA.
Chapter 5 helps understand study findings; discusses their importance to current
literature, and presents conclusions. This next chapter also discusses the social change
implications of the study results and conclusions, the limitations of the current study, and
further recommendations for future research in this area.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Evidence shows that the population of patients with diabetes is disproportionately
affected by arthritis in general; however, there is no recognized association between
T2DM and RA. Up to this point, the available research has been unclear about the
existence and nature of the association between T2DM and RA. This is why health care
providers do not consider this comorbidity as part of the management of these two
individual diseases. Because these two conditions have several factors in common, it is
important to understand whether they are related and whether they should be managed in
a interdisciplinary manner to achieve better patient outcomes. The present study was
performed on a nationally representative sample to clarify the relationship between
T2DM and RA, and to assess potential demographic, lifestyle, and clinical factors that
could be relevant.
Using six 2-year data sets (data from 1999 to 2012) from the continuous
NHANES, the present study examined the cross-sectional association between T2DM and
comorbid RA. Statistical analysis was used to assess the prevalence and adjusted ORs for
this association after adjusting for the following confounders: age, gender, ethnicity,
education, and smoking status. The 1999-2012 data sets—which were used to assess the
primary study hypotheses—allowed for assessments of a higher statistical power (N =
31,488) compared to previous research. The combined data set was used to compare
differences between participants with both T2DM and RA; with T2DM and no presence
of RA; with RA and with no presence T2DM; and without either diagnosis. The results

125
demonstrated that there was a strong association between RA and T2DM after adjusting
for potential confounders. It was found higher prevalence of RA in participants with
T2DM in comparison with those without T2DM and the general population as well as
higher prevalence of T2DM in participants with RA. Relevant factors in this crosssectional association between T2DM and RA were gender, ethnicity, education, obesity,
hypertension, disability, and work functioning.
Using the same methodology, the study also investigated the prevalence of CVD,
which is a primary cause of death in the United States, in participants with the
comorbidity (T2DM and RA). The prevalence of CVD among participants with comorbid
T2DM and RA is approximately two times the prevalence of having CVD when
participants have only one of these conditions and about four times the prevalence of
having CVD in comparison with those not having any of these conditions. Previous
research indicated that the prevalence of CVD was similar in patients with T2DM and
RA independently; which was higher than the prevalence of CVD in the general
population. The current study reinforced previous research but also demonstrated that the
prevalence of CVD is even higher in participants with T2DM and comorbid RA in
comparison with those participants having only one of these diseases. Until now, no data
have been available that evaluated the prevalence of CVD in patients with presence of
both conditions.
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Summary and Interpretation of Findings
T2DM and RA
The present study results indicated that the prevalence of RA in participants with
T2DM was higher than those participants without evidence of T2DM. It is important to
note the importance of adjustment for the different potential confounders (age, gender,
ethnicity, education, and smoking status) while evaluating the association between these
two conditions. After adjustment, the ORs of the association changed; however, the OR
of association remained statistically significant supporting strong association between the
dependent and independent variable. The finding persisted after controlling for potential
confounders. Previous research has suggested a potential association between T2DM and
RA; however, the majority of the research was not designed to investigate this specific
association and thus the results were not enough strong to make conclusions. Only a few
studies have been conducted to investigate this specific association and most had
limitations that don’t allow making conclusions on this topic. One of the most relevant
studies in this area was performed by Simard and Mittleman (2007). The results showed
no association between RA and DM. Their study was somewhat limited because it did
not include the general population, but only people aged 60 years old and over and only
evaluated data from 1988 to 1994. The current study went beyond the work done by
Simard and Mittleman using a larger and more representative including all adults
(18 years old and older) sample along with better power . The current study analysis was
adjusted by age to mitigate any bias in this area. Tentolouris (2008) also evaluated the
risk of RA in T2DM previously in a 10-year longitudinal study and noticed that the risk
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of RA was associated with T2DM; however, the sample was too small to make
conclusions. The current study complements the previous longitudinal research made by
Tentolouris supporting the association between T2DM and RA. In another study,
Solomon looked at this association from a different perspective evaluating the risk of
T2DM in patients with RA. He found an association; however, he established that the
work needed replication before making any conclusion. As part of the current study, the
prevalence of T2DM in participants with RA was also evaluated as well as the OR for
this association, and it was found that prevalence of T2DM was higher in participants
with RA than in participants without RA or also in comparison with the prevalence in the
general population. The authors also notice this association decreased with age, a variable
that was adjusted in the current research as previously mentioned.
Another study in this area was completed by Dubreuil et al. in 2012 where the
authors evaluated the risk of incident diabetes in PsA and RA in the general population,
with adjustment for BMI and lifestyle factors. This research used electronic medical
records database representative of the UK general population. As a result, it was found
that the risk of incident DM in RA was significantly elevated, but only due to BMI and
smoking. In the current study, smoking was included as one of the variables used for
adjustment. BMI was added to the adjustment and the OR of the association between
T2DM and RA remains strong (OR: 1.3; 95% CI: 1.1 to 1.5, p > 0.006). There is
additional indirect research data related to this comorbidity; however, the main purpose
of the research was not to evaluate this association and thus results might only be used to
generate hypotheses but not to make conclusions.
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Recently Jiang, et al published a new study that investigated this association using
a meta-analysis to explore the risk of DM in RA patients. The conclusion of such study
indicates that RA is associated with increased risk of DM, including T1DM and T2DM
which support the results of the current research (Jiang et al., 2015).
Important Factors or Characteristics
The current study also evaluated potential demographic, lifestyle, and clinical
characteristics or factors that could be relevant in this association using a nationally
representative sample.
Demographic characteristics. The demographic characteristics evaluated in the
research were age, gender, race/ethnicity, education level, and poverty level.
Age: It is well known, that the risk of developing arthritis (most types of arthritis
including RA) increases with age. The risk of T2DM increases with age especially after
age 45 probably because people tend to exercise less, lose muscle mass, and gain weight
as they age. As expected, results of the study indicated that participants with T2DM and
comorbid RA were older than those with only one of the diseases. The mean age of
participants with T2DM alone was higher than those with only diagnosis of RA and at the
same time much higher than those with no evidence of T2DM or RA.
Gender: Taking gender in consideration, it is known that most types of arthritis
are more common in women because 60% of all people with arthritis are females. In
general, no significant difference has been found by gender for diabetes. In the general
population for the study, the proportion of participants by gender were almost even (51%
female: 49% male); however, when participants were segregated by presence of disease it
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was found that participants with diagnosis of RA (with or without T2DM) were more
likely to be female. This was more pronounced in the case of participants with RA with
comorbid T2DM.
Race and ethnicity: Based on previous literature, blacks, Hispanics, American
Indians, and Asian-Americans are more likely to develop T2DM than whites. In general,
no significant difference has been found by race or ethnicity for arthritis. The study
results showed a significant difference in the proportion of non-Hispanic blacks within
this comorbidity. The proportion of non-Hispanic blacks was higher in the group with
this T2DM and RA than the group with only RA or only T2DM suggesting that this
particular ethnicity is more affected by the combination of these two conditions.
Education: Some literature indicates that education level is an important marker
of clinical status in RA (Callahan & Pincus, 1988). Previous research on diabetes has
suggested that “less than a high school education” had the highest rate among the
educational levels for patients with DM (Mokdad et al., 2001). It is important to consider
that risk factors such as smoking, inactivity, and medication regimen noncompliance are
more prevalent in those patients who have a lower educational level (high school or less)
compared with those classified with higher education level (more than high school). The
results of this study supported previous research because the proportion of participants
with “less than a high school education” were significantly higher in participants with
both conditions (T2DM and RA). This confirmed that patients with lower level of
education (“less than a high school education”) are likely to be sicker than those with
higher education.
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Poverty: As indicated in previous chapters, the poverty levels set minimum
amount of gross income a family needs for food, clothing, transportation, shelter, and
other necessities. PIR values below 1.00 considered as being below the official poverty
threshold (poor), whereas PIR values of 1.00 or greater indicating income values above
the poverty level. Poverty is an important factor in DM because poor people are less able
to afford basic elements like healthy food to manage their disease. Both T2DM and RA
are possible causes for disability and unemployment, which lead to lack of productivity
and are related to low poverty levels. The study results indicated that the PIR is similar in
participants with T2DM or RA independently; however, it decreased with the
combination of both conditions and increased with no evidence of RA or T2DM. The
results suggested that lower poverty status is associated with increased sickness.
Lifestyle Characteristics. Factors related to patients’ lifestyle that were
evaluated in this investigation were smoking, disability, and work functioning.
Smoking Status: There is plenty of evidence that relates both DM and RA with
smoking. Smoking cigarettes increases the risk of RA and DM; while quitting smoking
can reduce the risk. The data from the present research indicated that smoking status
appeared to be more associated with RA among the non-T2DM group than the T2DM
group. For instance, past smokers in the non-T2DM group had greater odds of RA
compared to the same odds for the T2DM group. The finding suggested that more
patients with T2DM stop smoking after the diagnosis.
Disability: Disability is an important factor to consider because arthritis and other
rheumatic conditions are the most common cause of disability among U.S. adults. Forty-
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two percent of adults with doctor-diagnosed arthritis report arthritis-attributable activity
limitations. The NHIS has found that disability affects an estimated 20–50% of patients
with diabetes. Previous literature has established that patients with diabetes, in general,
report rates of disability that are substantially higher than those reported by the general
U.S. population (CDC, 2006; Mayfield, 1999; Aubert, 1995). In the current study, we
corroborated that both physical and mental disabilityare significantly higher for those
participants with RA alone and also with T2DM, which is consistent with the information
available up to this point. In addition to this, it was noted that disability is even more
marked in those participants that carry both conditions. This affects both physical and
mental disability but is more relevant with physical disability.
Work Functioning: Similarly, looking into work functioning, the results followed
the same direction with a significant proportion of participants with T2DM and comorbid
RA reporting inability to work. This statement was also applicable to participants with
the individual diseases with rates higher than in the general population and lower than
participants with the comorbidity of T2DM and RA. Intyerestingly, those with reduced
work functionality were associated with RA diagnosis, but this had greater impact on the
non-T2DM group compared to the T2DM group. Further work would be required to
determine whether the impact is less on the T2DM group because their work
functionality is already decreased due to their DM.
After evaluating demographic and lifestyle characteristics, it is important to
mention the importance of socio economic status (SES) of these patients. SES primarily
constitutes material and financial resources (e.g., income/wealth [PIR]), occupation
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(disability and work functioning), and knowledge (e.g., education levels), all of which
either act independently or in combination to influence health. The combination of all
these elements is important to evaluate in a multifactorial manner while treating diseases
like T2DM and RA and could be even more cumbersome when managing combinations
of diseases. The effect of SES could affect the ability to effectively manage disease and
also patients’ motivation to achieve adequate health.
Clinical characteristics. Clinical characteristics evaluated in this investigation
were hypertension, blood pressure levels, BMI, lipid levels (HDL/LDL, TC), CRP,
glucose, HbA1c levels, and the use of some medications commonly used to treat arthritis.
The study evaluated the blood pressure levels as a continuous variable and
hypertension as a categorical variable considering the following categories: normal,
prehypertension, and hypertension. Previous research indicated that there is association
between hypertension and diabetes as well as its complications including micro- and
macrovascular disease. RA, as well as DM, has evidence of association with elevated risk
of CVD, which is attributed to several potential factors including hypertension.
Hypertension is highly prevalent but seems to be underdiagnosed and undertreated
among patients with RA (Panoulas et al., 2008). The present study clearly demonstrated
that hypertension is highly predominant in participants with T2DM and comorbid RA as
well as in participants with T2DM in comparison with participants with no T2DM.
Participants with only RA were less likely to have hypertension in comparison to those
with only T2DM; however, the proportion was significantly increased in comparison with
participants with no evidence of RA or T2DM.
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The current study also evaluated BMI as a continuous variable and as a
categorical variable based on the following weight categories: normal, overweight, and
obese. BMI is considered an independent risk factor for both T2DM and RA. It is well
documented that obese people have a higher risk of developing arthritis, and being
overweight is a primary risk factor for T2DM. The study results supported the above
statement since BMI was higher in those participants with the presence of T2DM; with
RA or without RA versus those with RA alone or participants with no presence of RA or
T2DM. It was found that participants with T2DM and RA have the same BMI as those
with T2DM alone, which could indicate that T2DM is highly affected by increased BMI.
BMI for participants with RA alone was significantly lower in comparison with those
with presence of T2DM but significantly higher in comparison with those with no
presence of these two diseases. The findings suggested that obesity is a significant factor
in both conditions with a higher relevance on those with presence of T2DM. The results
following the weight categories confirmed the previous statement based on BMI
indicating that there is more obesity in participants with presence of T2DM with or
without RA; however participants with RA alone are significantly more obese than those
with no without presence of RA or T2DM.
Lipids were not found to be significantly different within these groups; except for
TC, which was higher in those participants with positive RA.
Inflammation is an important element to consider in the potential relationship
between T2DM and RA. One of the methods used to assess inflammation is using CRP in
which elevated levels can provide support for the presence of inflammation. The study
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found no significant difference in CRP between participants with T2DM and comorbid
RA in comparison with those participants with individual diseases; however the CRP
levels for all groups (T2DM and RA, T2DM alone, and RA alone) were significantly
higher than those without evidence of disease (T2DM or RA). The levels of CRP were
not significantly higher in participants with both conditions in comparison with those
with individual diseases (T2DM and RA).
Plasma glucose and HbA1c are elements to consider for the diagnostic of diabetes
and to assess glycemic control. Plasma glucose is also important to identify episodes of
hypoglycemia or hyperglycemia. As expected, the study results indicated that participants
with positive diagnosis of T2DM have higher glucose and HbA1c levels. Interestingly,
but not significant, it was found that participants with both conditions have slightly better
glycemic control based on glucose and HbA1c levels than those with only T2DM. This
could be based on better patient control and disease management as comorbidities
increased. Some treatments of RA are known to affect glucose levels. In those
participants with no presence of T2DM, there was a small but significant difference
between those with or without RA that could be related to the use of the previously
mentioned drugs. The study also evaluated the use of some of these treatments: (a)
antirheumatic drugs including biologic response modifiers; (b) glucocorticoids; and (c)
analgesics. As expected, the results indicated that participants with positive diagnosis to
RA (with or without T2DM) have a higher use of these drugs; however, participants with
positive diagnosis of T2DM use these types of medication more than the general
population.
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CVD in participants with T2DM and comorbid RA.
As previously described in Chapter 2, there is a substantial amount of evidence
for the increased cardiovascular risk in RA which is comparable to what is found in
T2DM; however, there were no data available that describe the prevalence of CVD in
patients with T2DM and comorbid RA. Potential factors associated with CVD and RA
are obesity, insulin resistance, hypertension, atherosclerosis, dyslipidemia
(Stamatelopoulos et al., 2009a), and inflammation (Sattar et al., 2003). CVD has been
identified as the major complication of diabetes and is the primary cause of early death
among people with this condition (NIH, 2007). It is recognized that both conditions, DM
and RA, are connected with an increased risk of CVD.
The current investigation evaluated the prevalence of CVD in participants with
T2DM and concomitant RA and found that the prevalence and ORs of association of
CVD among participants with comorbid T2DM and RA is approximately two times the
possibility of having CVD when participants have one of these conditions and about four
times the possibility of having CVD in comparison with those not having any of these
conditions or those in the general population. As previously mentioned, there are several
investigations evaluating the risk of CVD in these individual diseases (T2DM and RA)
and comparing the risk between the two disesase. The present study supported previous
research finding a similar prevalence of CVD between both diseases; however, it
exceeded previous research by demonstrating that CVD is even higher in those
participants with this comorbidity of T2DM and RA.
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Conclusion
In conclusion, the present study provides evidence supporting a strong association
between T2DM and concomitant RA. Prevalence of RA is significantly higher in
participants with T2DM in comparison with those with no diagnosis of T2DM. Important
factors in common in this association are gender, ethnicity, education, disability, and
work functioning, which significantly increase the OR of association for RA in
participants with diagnosed T2DM.
Finally, prevalence of CVD and adjusted OR of association are double in
participants with T2DM and comorbid RA in comparison with participants with just one
of the conditions andfour times higher if compared with those with no comorbidity or
with the general population.
Significance of the Study
The current study is the first one assessing the relationship between T2DM and
RA using continuous NHANES data. A previous study assessed this relationship using
NHANES III (not continuous data) and it was limited to elderly (65 years and older); In
contrast, the current study included participants 20 years old and older and covered 12
years of data (1999-2012), which increased the sample size while improving the power of
the study. Using this type of data set gave the study the strength of representativeness of
the data since study participants constituted a large nationally representative sample of
noninstitutionalized adults. The NHANES data set also allowed for the collection and
assessments of a wide range of known confounding variables, which were controlled for
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during the analysis, as well as sampling methodology that allowed accounting for special
populations that are not normally considered in other database studies.
These strengths address some limitations found in previous studies, including
sample size, potential confounding and selection bias due to failure to control for
important factors, and nonrandom sampling. The sampling strategy used by NHANES
decreases the opportunity of having selection bias and at the same time increases
reliability of the data analysis. The continuous design brings flexibility to combine and
analyze data over several cycles of two years increasing sample size.
The current study adds new hypotheses related to the association between T2DM
and RA that warrant further investigation in prospective and longitudinal studies that
could demonstrate causality. The study findings also support and reinforce the results of
several previous studies on the prevalence or risk of CVD in patients with T2DM and RA
independently; however, it is the first study to investigate the prevalence of CVD in
patients with T2DM and comorbid RA. Along the same line, additional research is
needed in this area to understand important factors in this comorbidity (T2DM, RA, and
CVD) and to investigate potential causality.
Limitations
This is secondary analyses of cross-sectional data (data captured in one point in
time), which does not allow determination of temporality of the association between
T2DM and RA; therefore, no causal relationships conclusion should be made in this case.
The primary objective of the study was to determine prevalence, thus the design was
appropriate for the purpose. However, ideally once an association is shown, the next step
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is to understand the nature of the association; and the current study cannot make any
determination in this matter. In order to mitigate this limitation, additional analysis was
performed taking in consideration the date from diagnosis for RA and T2DM, which
gives the opportunity to understand the proportion of participants who reported diagnosis
of T2DM before RA or vice versa in those participants with diagnosis of both conditions.
The same analysis was performed with CVD to understand this variable within the last
objective of the study (prevalence of CVD in participants with T2DM and comorbid RA).
Because the NHANES collects data from noninstitutionalized individuals, it may
exclude some population groups at higher risk for both T2DM and RA, including
residents of institutionalized settings (e.g., nursing homes) and persons of lower
socioeconomic status without a home or home address. It may also exclude
generalizations (external validity) to other countries especially with different health care
systems. To mitigate potential selection bias, the present study findings are generalized to
noninstitutionalized adults with T2DM and RA in the United States. Also because T2DM
as well as RA are known to lead to mental and physical disability, a subset of disabled
patients may not be included in the study and conclusions regarding this population are
not be possible.
The diagnosis of RA and T2DM were self-reported by participants, which may
lead to underreporting of diagnoses and misclassification bias; however, previous studies
have found consistency between self-reported data on diabetes and data that were
confirmed via medical records.
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Another limitation related to the diagnosis of T2DM is that there is no defined
variable for T2DM and thus a previously documented algorithm was used to identify
patients with T2DM from all patients with diabetes. T1DM was operationally defined as
an age of onset less than 30 years and receiving insulin treatment within a year after
diagnosis; which resulted in the exclusion of a considerable number of persons with
diabetes. The possibility that some of these individuals may have been patients with
T2DM should be considered; however, use of this definition is supported by previous
studies as previously stated. Future longitudinal studies or with specific diabetes
diagnosis (T2DM or T1DM) are recommended to complement these findings.
Implications for Social Change and Recommendations for Action
The current study has several implications for social change. Considering the
clinical perspective, this study supports that a different attention is needed from health
care providers while managing patients with T2DM and concomitant RA; in particular,
considering the elevated probability of having CVD, which is primary cause of death in
the United States. The findings add to the evidence suggesting that there is a strong
association between T2DM and RA. Furthermore, this study added characterization and
identification of specific differences between patients with T2DM and RA; T2DM and no
RA; RA and no T2DM; and those with no disease with regard to demographic, lifestyle,
and clinical factors. The findings may aid health care providers (e.g., endocrinologists,
diabetes educators, and nurses), especially busy primary care physicians (PCPs), to
characterize and identify a population that could be at high risk for having one disease,
which will facilitate targeted screening, early detection, and treatment of the second
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disease or vice versa. Also, for those patients that already have both diseases, the HCP in
particular the PCP, that in many cases manage all diseases in a interdisciplinary manner,
may use a different approach that could address all patients’ needs.
The findings provide evidence that ethnicity is an important factor to consider, as
shown by a significantly higher proportion of non-Hispanics lacks with positive diagnosis
of T2DM and comorbid RA when compared to those with individual diseases or no
presence of either of the two diseases. Additionally age (older patients); gender (highly in
females), and education (less educated people) are important factors to consider while
attending to patients at risk of this comorbidity.
The present study results suggest CVD is highly prevalent in patients with T2DM
and comorbid RA. With the caveat that it is not possible to determine causality, it is
important for health care providers to grant additional importance to the cardiovascular
risk in patients with this comorbidity of T2DM and RA. This study further emphasizes
the need for effective screening and early diagnosis of CVD in this population.
By strengthening current evidence, these findings can serve as input for policy
and/or decision makers, which may to help inform policies to improve patients’ health.
Based on this and further data, screening and targeted public health intervention
approaches could be implemented in particular to manage these diseases in a
multifactorial or interdisciplinary manner as supported by the CCM.
From a research standpoint, current study findings indicate strong association
between T2DM and RA and highlight potential factors to consider in this association;
however, additional research is needed to understand the nature of this association; which
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disease could predict the other one and also which factors could be predictors versus
consequences of the interaction between these comorbidites. Longitudinal data is needed
to understand all factors that could affect this association and also recognize the
multilevel environment that could affect the individual support as well as the
organizational (provider – community) perspective considering the SEM theory.
As future studies are designed to examine the relationship between T2DM and
RA, the mediating effects of factors like disability and work functioning need to be taken
into consideration in addition to known potentially confounding factors (age, gender,
ethnicity, education, and smoking status). Further longitudinal studies are needed to
determine causal relationship that could help identify groups at risk for the appropriate
prevention and/or interventions.
The findings also demonstrate that patients with T2DM and comorbid RA are
more likely to have CVD. It is important to characterize patients with evidence of T2DM,
RA, and comorbid CVD and how they differ with those patients with CVD and only one
of these conditions (T2DM and RA). Once potential predictors are defined, it is possible
to create interventions for disease detection and treatment as well of management of
complications in an appropriate and timely manner. Longitudinal studies are needed to
understand temporal association between these diseases and to understand possible
predictors or links between causatives precursors. Additional research may help inform
HCPs how to manage these diseases in a interdisciplinary manner following the CCM.
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